<SEC-DOCUMENT>0001299933-12-001146.txt : 20120510
<SEC-HEADER>0001299933-12-001146.hdr.sgml : 20120510
<ACCEPTANCE-DATETIME>20120510160841
ACCESSION NUMBER:		0001299933-12-001146
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20120510
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20120510
DATE AS OF CHANGE:		20120510

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			STEMCELLS INC
		CENTRAL INDEX KEY:			0000883975
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				943078125
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19871
		FILM NUMBER:		12830377

	BUSINESS ADDRESS:	
		STREET 1:		3155 PORTER DRIVE
		STREET 2:		.
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94304
		BUSINESS PHONE:		6504753100

	MAIL ADDRESS:	
		STREET 1:		3155 PORTER DRIVE
		STREET 2:		.
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94304

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CYTOTHERAPEUTICS INC/DE
		DATE OF NAME CHANGE:	19930328
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>htm_45025.htm
<DESCRIPTION>LIVE FILING
<TEXT>
<!-- CoverPageHeader start -->
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 3.2//EN">
<HTML>
<HEAD>
<TITLE> StemCells, Inc. (Form: 8-K) </TITLE>
</HEAD>
<BODY TEXT="#000000" BGCOLOR="#FFFFFF" ALINK="#0000FF" HLINK="#FF0000" VLINK="#800080">
<!-- Comment1 -->
<A NAME="DOCUMENT_TOP">&nbsp;</A>
<P>
<!-- CoverPageHeader end --><!-- CoverPageTitle START -->
<A NAME="DOCUMENT_TOP">&nbsp;</A>
<HR NOSHADE>
<P>
<P ALIGN="CENTER">
<FONT SIZE="4">
		UNITED STATES<BR>
	SECURITIES AND EXCHANGE COMMISSION
</FONT>
<BR>
<FONT SIZE="2">
	WASHINGTON, D.C. 20549
</FONT>
<P ALIGN="CENTER">
<FONT SIZE="5">
	FORM 8-K
</FONT>
<FONT SIZE="2">

</FONT>
</P>
<P ALIGN="CENTER">
<FONT SIZE="3">
	CURRENT REPORT
</FONT>
</P>
<P ALIGN="CENTER">
<FONT SIZE="2">
	Pursuant to Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934
</FONT>
</P>
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="100%">
<TR VALIGN="BOTTOM">
<TD WIDTH="51%">
	&nbsp;
</TD>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="44%">
	&nbsp;
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	Date of Report (Date of Earliest Event Reported):
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	May 10, 2012
</FONT>
</TD>
</TR>
</TABLE>
<BR>
</CENTER>
<!-- CoverPageTitle END --><!-- CoverPageRegistrant START -->
<P ALIGN="CENTER"><!-- -->
<FONT SIZE="6">
	StemCells, Inc.
</FONT>
<FONT SIZE="2">
<BR>__________________________________________<BR>
	(Exact name of registrant as specified in its charter)
</FONT>
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="100%">
<TR VALIGN="BOTTOM">
<TD WIDTH="33%">
	&nbsp;
</TD>
<TD WIDTH="34%">
	&nbsp;
</TD>
<TD WIDTH="33%">
	&nbsp;
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	Delaware
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	000-19871
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	94-3078125
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
_____________________<BR>
	(State or other jurisdiction
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
_____________<BR>
	(Commission
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
______________<BR>
	(I.R.S. Employer
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	of incorporation)
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	File Number)
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	Identification No.)
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	7707 Gateway Blvd, Suite 140, Newark, California
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	94560
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
_________________________________<BR>
	(Address of principal executive offices)
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
___________<BR>
	(Zip Code)
</FONT>
</TD>
</TR>
</TABLE>
</CENTER>
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="100%">

<TR VALIGN="BOTTOM">
<TD WIDTH="51%">
	&nbsp;
</TD>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="44%">
	&nbsp;
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	Registrant&#146;s telephone number, including area code:
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	510.456.4000
</FONT>
</TD>
</TR>
</TABLE>
</CENTER>
<P ALIGN="CENTER">
<FONT SIZE="2">
	Not Applicable
<BR>______________________________________________<BR>
	Former name or former address, if changed since last report
</FONT>
<P ALIGN="CENTER">
<FONT SIZE="2">
	&nbsp;
</FONT>
<!-- CoverPageRegistrant END --><P><FONT SIZE="2">
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any
of the following provisions:</FONT>
</P>
<P><FONT SIZE="2">
[&nbsp;&nbsp;]&nbsp;&nbsp;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)<br>
[&nbsp;&nbsp;]&nbsp;&nbsp;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<br>
[&nbsp;&nbsp;]&nbsp;&nbsp;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<br>
[&nbsp;&nbsp;]&nbsp;&nbsp;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))<br>
</P></FONT><!-- PageBreak START -->
<P>
<HR NOSHADE>
<DIV ALIGN="LEFT" STYLE="PAGE-BREAK-BEFORE:ALWAYS">
<A HREF="#DOCUMENT_TOP">
<U>
<B>
<FONT SIZE="2">Top of the Form</FONT>
</B>
</U>
</A>
</DIV>
<!-- PageBreak END --><!-- Item START -->
<P ALIGN="LEFT">
<FONT SIZE="2">
<B>
	Item 2.02 Results of Operations and Financial Condition.
</B>
</FONT>
</P>
<P ALIGN="LEFT">
<FONT SIZE="2">
On May 10, 2012, StemCells, Inc. (the "Company") issued a press release announcing its financial results for the three months ended March 31, 2012. A copy of this press release is attached hereto as Exhibit 99.1.<br><br>StemCells will host a live conference call and webcast today, May 10, at 4:30 PM Eastern Time (1:30 PM Pacific Time) to discuss its financial results and recent business activities. Interested parties are invited to listen to the call over the Internet via the Investors section of the Company&#x2019;s website at http://investor.stemcellsinc.com/phoenix.zhtml?c=86230&p=irol-irhome. An archived version of the webcast will be available for replay on the Company&#x2019;s website beginning approximately two hours following the conclusion of the live call and continuing for a period of 30 days. <br><br>The information set forth in Items 2.02 and 9.01 of this current report Form 8-K, including the attached exhibit, is being furnished to the SEC and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended ("Exchange Act"), or otherwise subject to the liabilities of such section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.<br>
</FONT>
</P>
<!-- Item END -->
<BR><BR><BR><BR><!-- Item START -->
<P ALIGN="LEFT">
<FONT SIZE="2">
<B>
	Item 9.01 Financial Statements and Exhibits.
</B>
</FONT>
</P>
<P ALIGN="LEFT">
<FONT SIZE="2">
(d) Exhibits<br><br>Exhibit 99.1 Press Release, dated May 10, 2012, announcing the Company's financial results for the three months ended March 31, 2012.
</FONT>
</P>
<!-- Item END -->
<BR><BR><BR><BR><P ALIGN="LEFT" STYLE="FONT-SIZE: 10PT"></P><!-- PageBreak START -->
<P>
<HR NOSHADE>
<DIV ALIGN="LEFT" STYLE="PAGE-BREAK-BEFORE:ALWAYS">
<A HREF="#DOCUMENT_TOP">
<U>
<B>
<FONT SIZE="2">Top of the Form</FONT>
</B>
</U>
</A>
</DIV>
<!-- PageBreak END --><!-- SignatureHeader START -->
<P ALIGN="CENTER">
<FONT SIZE="2">
<B>
	SIGNATURES
</B>
</FONT>
</P>
<P ALIGN="LEFT">
<FONT SIZE="2">
	Pursuant to the requirements of the Securities Exchange Act of 1934, the
	registrant has duly caused this report to be signed on its behalf by the
	undersigned hereunto duly authorized.
</FONT>
</P>
<!-- SignatureHeader END --><!-- Signature START -->
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="100%">
<TR VALIGN="BOTTOM">
<TD WIDTH="19%">
	&nbsp;
</TD>
<TD WIDTH="34%">
	&nbsp;
</TD>
<TD WIDTH="3%">
	&nbsp;
</TD>
<TD WIDTH="1%">
	&nbsp;
</TD>
<TD WIDTH="43%">
	&nbsp;
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" VALIGN="TOP" ALIGN="LEFT">
<FONT SIZE="2">
	StemCells, Inc.
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
<I>
	May 10, 2012
</I>
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
<I>
	By:
</I>
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
<I>
	/s/ Kenneth Stratton
</I>
<BR>
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<HR SIZE="1" NOSHADE>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
<I>
	Name: Kenneth Stratton
</I>
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
<I>
	Title: General Counsel
</I>
</FONT>
</TD>
</TR>
</TABLE>
</CENTER>
<!-- Signature END --><!-- PageBreak START -->
<P>
<HR NOSHADE>
<DIV ALIGN="LEFT" STYLE="PAGE-BREAK-BEFORE:ALWAYS">
<A HREF="#DOCUMENT_TOP">
<U>
<B>
<FONT SIZE="2">Top of the Form</FONT>
</B>
</U>
</A>
</DIV>
<!-- PageBreak END --><P ALIGN="CENTER">
<FONT SIZE="2">
	Exhibit&nbsp;Index
</FONT>
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="60%">
<TR VALIGN="BOTTOM">
<TD WIDTH="8%">
	&nbsp;
</TD>
<TD WIDTH="15%">
	&nbsp;
</TD>
<TD WIDTH="77%">
	&nbsp;
</TD>
</TR>

<BR>
<TR VALIGN="BOTTOM">
<TD NOWRAP ALIGN="LEFT">
<FONT SIZE="1">
<B>
	Exhibit No.
</B>
</FONT>
</TD>
<TD>
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP ALIGN="LEFT">
<FONT SIZE="1">
<B>
	Description
</B>
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD NOWRAP ALIGN="CENTER">
<HR SIZE="1" NOSHADE>
</TD>
<TD>
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP ALIGN="CENTER">
<HR ALIGN="LEFT" SIZE="1" WIDTH="88%" NOSHADE>
</TD>
</TR>





<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" WIDTH="8%" nowrap>
<FONT SIZE="2">
<DIV ALIGN="LEFT">
	99.1
</DIV>
</FONT>
</TD>
<TD WIDTH="15%">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP" WIDTH="77%">
<FONT SIZE="2">
Press Release of StemCells, Inc. dated May 10, 2012
</FONT>
</TD>
</TR></TABLE></CENTER><!-- HTMLFooter START -->
</BODY>
</HTML>
<!-- HTMLFooter END -->
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 3.2//EN">
<HTML>
<HEAD>
<TITLE> EX-99.1 </TITLE>
</HEAD>
<BODY TEXT="#000000" BGCOLOR="#FFFFFF" ALINK="#0000FF" HLINK="#FF0000" VLINK="#800080">

<BODY style="font-family: 'Times New Roman',Times,serif">


<P align="left" style="font-size: 10pt"><FONT style="font-size: 11pt"><img src="e36190-121311440541954ccf_1.jpg">
</FONT>

<P align="center" style="font-size: 11pt"><B>STEMCELLS, INC. REPORTS FIRST QUARTER 2012 FINANCIAL RESULTS<BR>
AND PROVIDES BUSINESS UPDATE</B>



<P align="left" style="font-size: 11pt"><B>NEWARK, CA (May&nbsp;10, 2012) </B>&#150; StemCells, Inc. (NASDAQ: STEM), a leading stem cell company developing
and commercializing novel cell-based therapeutics and tools for use in stem cell-based research and
drug discovery, today reported financial results for the first quarter ended March&nbsp;31, 2012 and
provided a business update.


<P align="left" style="font-size: 11pt">&#147;The first quarter of 2012 turned out to be pivotal in the Company&#146;s pursuit of cell-based
therapeutics for a broad array of CNS disorders,&#148; said Martin McGlynn, President and CEO of
StemCells, Inc. &#147;Data from our Phase I trial completed in February, which was designed to evaluate
the safety and preliminary efficacy of our proprietary HuCNS-SC&#174; neural stem cells in a rare
myelination disorder, provided us with the clinical breakthrough that we had been seeking. We have
now established proof of principle that our cells are capable of myelinating nerve axons in an
appropriate, progressive and durable way in the brains of patients with a severe myelination
disorder. Moreover, we observed measurable gains in motor and/or cognitive function in three of the
four patients, while the fourth remained clinically stable. We believe this is a departure from
the natural history of this fatal disease. This is great news for the PMD community and in due
course we will meet with the FDA to discuss the conduct of a controlled Phase II study. The
results of the study should also provide encouragement to the large community of patients,
caregivers and clinicians dealing with more common myelination disorders, such as multiple
sclerosis and cerebral palsy. We now plan to meet with experts to help us develop a strategy to
quickly and efficiently evaluate our cells in these more common myelination disorders.&#148;


<P align="left" style="font-size: 11pt">&#147;It remains our belief,&#148; continued Mr.&nbsp;McGlynn, &#147;that the best pathway for growing shareholder
value is for the Company to continue generating meaningful clinical data for our HuCNS-SC program
in a thoughtful, cost effective manner. As our financial results show, we are carefully
controlling our expenses and our cash burn. And as our PMD trial data shows, meaningful data from
our extensive and expanding clinical development program has begun to emerge.&#148;


<P align="left" style="font-size: 11pt"><B>First Quarter and Recent Business Highlights</B>


<P align="left" style="font-size: 11pt"><U>Therapeutic Product Development</U>


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 11pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">&#149;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In January&nbsp;2012, we published preclinical data demonstrating that our HuCNS-SC cells
protect host photoreceptors and preserve vision in a well-established animal model of
retinal disease. Moreover, the number of cone photoreceptors, which are responsible for
central vision, remained constant over an extended period. The preclinical results are
highly relevant to human disorders of vision loss, the most notable of which is dry
age-related macular degeneration (AMD). The data was featured as the cover article in the
February&nbsp;2012 issue of the international peer-reviewed <I>European Journal of Neuroscience</I>.</TD>
</TR>

</TABLE>


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 11pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">&#149;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In January&nbsp;2012, the FDA authorized the initiation of a Phase I/II clinical trial of our
HuCNS-SC cells in dry AMD, the most common form of AMD. AMD is the leading cause of vision
loss and blindness in people over 55&nbsp;years of age, and approximately 30&nbsp;million people
worldwide are afflicted with the disease. There are no approved treatments for dry AMD.</TD>
</TR>

</TABLE>


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 11pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">&#149;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In March&nbsp;2012, a summary of the results of our Phase I PMD trial were reported at the
<I>European Leukodystrophy Association </I>Families/Scientists Meeting held in Paris, France. Data
from the trial provided preliminary evidence of durable and progressive donor cell-derived
myelination in all four patients transplanted with our HuCNS-SC cells. In addition, there
were measurable gains in neurological and/or motor function in three of the four patients;
the fourth patient was clinically stable.</TD>
</TR>

</TABLE>


<P align="left" style="font-size: 11pt"><U>Tools and Technologies Programs</U>


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 11pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">&#149;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In March&nbsp;2012, we entered into a license agreement under which we granted genOway SA a
worldwide, exclusive license to our Internal Ribosome Entry Site (IRES)&nbsp;technology for use
in the development and commercialization of genetically engineered mice. We received an
upfront license fee and could receive royalties on product sales.</TD>
</TR>

</TABLE>


<P align="left" style="font-size: 11pt"><U>Other Business Activities</U>


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 11pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">&#149;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In January&nbsp;2012, we submitted two applications to the California Institute of
Regenerative Medicine (CIRM)&nbsp;for &#147;Disease Team Therapy Development Research Awards,&#148; one
for Alzheimer&#146;s disease and one for cervical spinal cord injury. A Research Award may be
up to $20&nbsp;million, payable over four years, to fund preclinical and IND-enabling activities
with the aim of starting human clinical trials within a four-year window.</TD>
</TR>

</TABLE>


<P align="left" style="font-size: 11pt"><B>First Quarter Financial Results</B>


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 11pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">&#149;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Net cash used in operating activities down 24%</TD>
</TR>

</TABLE>


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 11pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">&#149;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Revenue from SC Proven product sales up 82%</TD>
</TR>

</TABLE>


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 11pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">&#149;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><I>Pro forma </I>cash balance of $13.7&nbsp;million &#151; includes $2.1&nbsp;million from warrant exercise</TD>
</TR>

</TABLE>


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 11pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">&#149;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Series&nbsp;B Warrants expired May 2 &#151;  no more outstanding</TD>
</TR>

</TABLE>


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 11pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">&#149;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Anticipated 2012 Cash Burn $18-20&nbsp;million</TD>
</TR>

</TABLE>


<P align="left" style="font-size: 11pt">Revenue from product sales in the first quarter of 2012 was $271,000, an 82% increase over the
first quarter of 2011. This growth was driven by increased unit volumes in our SC Proven media and
reagents business. Revenue from licensing agreements and grants in the first quarter of 2012 was
$373,000, due mainly to receipt of fees from a license agreement with genOway.


<P align="left" style="font-size: 11pt">Research and development expenses were 29% lower in the first quarter of 2012 compared to the same
period in 2011, while selling, general and administrative expenses declined by 7%. The significant
reduction in operating expenses was primarily attributable to the reduction in workforce effected
in May&nbsp;2011, relocation of our corporate headquarters in July&nbsp;2011 and other cost containment
measures.


<P align="left" style="font-size: 11pt">Loss from operations in the first quarter of 2012 was $5,326,000, a 29% decrease compared to the
first quarter of 2011. From a cash flow perspective, net cash used in operating activities in the
first quarter of 2012 was $5,631,000, which was 24% lower than the same period in 2011.


<P align="left" style="font-size: 11pt">Net loss for the first quarter of 2012 was $10,229,000, or $(0.45) per share, compared with a net
loss of $5,747,000, or $(0.42) per share, for the first quarter of 2011. The net loss in the first
quarter of 2012 includes a non-cash expense of $4,904,000 due to an increase in the estimated fair
value of warrant liability.


<P align="left" style="font-size: 11pt">At March&nbsp;31, 2012, <I>pro forma </I>cash, cash equivalents and marketable debt securities totaled
$13,702,000, which includes an estimated $2,100,000 in net proceeds from the exercise of Series&nbsp;B
Warrants. A total of 8,000,000 Series&nbsp;B Warrants were issued in December&nbsp;2011, of which 2,700,000
were exercised. The remaining 5,300,000 unexercised Series&nbsp;B Warrants expired by their terms on
May&nbsp;2, 2012.


<P align="left" style="font-size: 11pt"><B>Conference Call</B>


<P align="left" style="font-size: 11pt">StemCells will host a live conference call and webcast today, May&nbsp;10, at 4:30 PM Eastern Time (1:30
PM Pacific Time) to discuss our financial results and recent business activities. Interested
parties are invited to listen to the call over the Internet via the Investors section of our
website at <U>http://investor.stemcellsinc.com/phoenix.zhtml?c=86230&p=irol-irhome</U>. An
archived version of the webcast will be available for replay on our website beginning approximately
two hours following the conclusion of the live call and continuing for a period of 30&nbsp;days.


<P align="left" style="font-size: 11pt"><B>About StemCells, Inc.</B>


<P align="left" style="font-size: 11pt">StemCells, Inc. is engaged in the research, development, and commercialization of cell-based
therapeutics and tools for use in stem cell-based research and drug discovery. The Company&#146;s lead
therapeutic product candidate, HuCNS-SC&#174; cells (purified human neural stem cells), is currently in
development as a potential treatment for a broad range of central nervous system disorders.&nbsp;The
Company recently reported results from a Phase I clinical trial in Pelizaeus-Merzbacher disease
(PMD), a fatal myelination disorder in children. The trial results showed preliminary evidence of
progressive and durable donor-derived myelination in all four patients transplanted with HuCNS-SC
cells. The Company is also conducting a Phase I/II clinical trial in chronic spinal cord injury in
Switzerland and has received authorization from the FDA to initiate a Phase I/II clinical trial in
dry age-related macular degeneration (AMD). In addition, the Company is pursuing preclinical
studies of its HuCNS-SC cells in Alzheimer&#146;s disease.&nbsp;StemCells also markets stem cell research
products, including media and reagents, under the SC Proven&#174; brand. Further information about
StemCells is available at <U>http://www.stemcellsinc.com</U>.


<P align="left" style="font-size: 11pt"><I>Apart from statements of historical fact, the text of this press release constitutes
forward-looking statements within the meaning of the U.S. securities laws, and is subject to the
safe harbors created therein. These statements include, but are not limited to, statements
regarding the future business operations of StemCells, Inc. (the &#147;Company&#148;); the timing and
prospect associated with beginning to detect potential clinical benefit from the use of the
Company&#146;s HuCNS-SC cells; the prospect for continued clinical development of the Company&#146;s HuCNS-SC
cells in CNS disorders; the prospect for growth in the Company&#146;s product sales; the timing and
nature of the final data from the Company&#146;s Phase I clinical study in PMD; the timing of patient
dosing and possible outcomes of the Company&#146;s Phase&nbsp;I/II clinical study in spinal cord injury; the
Company&#146;s ability to apply for, and possibly secure in 2012, funding from the California Institute
of Regenerative Medicine; the adequacy of our existing supply of HuCNS-SC cells to complete our
ongoing and planned clinical trials; and the timing and prospects associated with initiating a
clinical trial in age-related macular degeneration. These forward-looking statements speak only as
of the date of this news release. The Company does not undertake to update any of these
forward-looking statements to reflect events or circumstances that occur after the date hereof.
Such statements reflect management&#146;s current views and are based on certain assumptions that may or
may not ultimately prove valid. The Company&#146;s actual results may vary materially from those
contemplated in such forward-looking statements due to risks and uncertainties to which the Company
is subject, including uncertainties with respect to the fact that additional trials will be
required to confirm the safety and demonstrate the efficacy of the Company&#146;s HuCNS-SC cells for the
treatment of spinal cord injury, PMD or any other condition; uncertainties about whether
myelination formed by donor cells, if any, will have any biologic effect; uncertainties about
whether preliminary data in any Phase&nbsp;I clinical study will prove to be reproducible or
biologically meaningful in any future clinical study; risks whether the FDA or other applicable
regulatory agencies will permit the Company to continue clinical testing in spinal cord injury, PMD
or in future clinical trials of proposed therapies for other diseases or conditions such as
age-related macular degeneration; uncertainties about the design of future clinical trials and
whether the Company will receive the necessary support of a clinical trial site and its
institutional review board to pursue future clinical trials in spinal cord injury, PMD, age-related
macular degeneration, or in proposed therapies for other diseases or conditions; uncertainties
regarding the potential for the Company to grow its SC Proven business and to advance the
development and commercialization of stem cell-based assays for drug discovery and development;
uncertainties regarding the Company&#146;s ability to obtain the increased capital resources needed to
continue its current and planned research and development operations, including such operations of
the Company for non-therapeutic applications, and to conduct the research, preclinical development
and clinical trials necessary for regulatory approvals; uncertainties about the Company&#146;s ability
to secure funding from any governmental agency, such as the California Institute of Regenerative
Medicine; uncertainty as to whether HuCNS-SC cells and any products that may be generated in the
future in the Company&#146;s cell-based programs will prove safe and clinically effective and not cause
tumors or other adverse side effects; uncertainties regarding whether results in preclinical
research in animals will be indicative of future clinical results in humans; uncertainties
regarding the Company&#146;s manufacturing capabilities given its increasing preclinical and clinical
commitments; uncertainties regarding the validity and enforceability of the Company&#146;s patents;
uncertainties as to whether the Company will become profitable; and other factors that are
described under the heading &#147;Risk Factors&#148; disclosed in Part&nbsp;I, Item&nbsp;1A in the Company&#146;s Annual
Report on </I><I>Form 10-K</I><I> for the year ended December&nbsp;31, 2011 and in its subsequent reports on Form&nbsp;10-Q
and </I><I>Form 8-K</I><I>.</I>


<P align="left" style="font-size: 11pt">CONTACT:


<P align="left" style="font-size: 11pt">Rodney Young
<BR>
StemCells, Inc.
<BR>
Chief Financial Officer
<BR>
(510)&nbsp;456-4128


<P align="left" style="font-size: 11pt">Ian Stone
<BR>
Russo Partners
<BR>
(619)&nbsp;308-6541


<P align="center" style="font-size: 11pt">&#151; more &#150;




<P align="center" style="font-size: 10pt; display: none">1
<!-- PAGEBREAK -->




<P align="left" style="font-size: 11pt"><FONT style="font-size: 10pt"><B>StemCells, Inc.</B>
<BR>
<B>Unaudited Condensed Consolidated Statements of Operations</B>
<BR>
(in thousands, except share and per share amounts)
</FONT>
<DIV align="center">
<TABLE style="font-size: 9pt" cellspacing="0" border="0" cellpadding="0" width="95%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="56%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom">
    <TD nowrap align="left">(unaudited)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000">&nbsp;</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom">
    <TD nowrap align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="11"><B>Three months ended</B></TD>
</TR>
<TR style="font-size: 9pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="11" style="border-bottom: 1px solid #000000"><B>March 31</B></TD>
</TR>
<TR style="font-size: 9pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>2012</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>2011</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Revenue:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:30px; text-indent:-10px">Revenue from licensing agreements and grants</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">373</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">72</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:20px; text-indent:-10px">Revenue from product sales</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">271</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">149</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Total revenue</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">644</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">221</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Cost of product sales</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">72</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">54</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Gross profit</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">572</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">167</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Operating expenses:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:30px; text-indent:-10px">Research and development</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,939</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5,525</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:40px; text-indent:-10px">Selling, general and administrative</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,924</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,076</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:30px; text-indent:-10px">Wind-down expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">35</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">75</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:40px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Total operating expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5,898</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">7,676</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Loss from operations</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">(5,326</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">(7,509</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Other income (expense):</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:30px; text-indent:-10px">Change in fair value of warrant liability</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">(4,941</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,783</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:30px; text-indent:-10px">Interest income (expense), net</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">(10</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">(19</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:30px; text-indent:-10px">Other income (expense), net</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">48</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">(2</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Total other income (expense), net</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">(4,903</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,762</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Net loss</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">$</TD>
    <TD align="right">(10,229</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">$</TD>
    <TD align="right">(5,747</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Basic and diluted net loss per share</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">$</TD>
    <TD align="right">(0.45</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">$</TD>
    <TD align="right">(0.42</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:40px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Shares used to compute basic and diluted</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:30px; text-indent:-10px">loss per share*</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">22,958,498</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">13,679,913</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:40px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="left" style="font-size: 9pt; text-indent: 5%"><FONT style="font-size: 8pt">* Adjusted for 1 for 10 reverse stock split
</FONT>

<P align="left" style="font-size: 8pt"><FONT style="font-size: 10pt"><B>StemCells, Inc.</B>
<BR>
<B>Unaudited Condensed Consolidated Balance Sheets</B>
<BR>
(in thousands)
</FONT>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="95%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="51%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="8%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="font-size: 10pt">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><FONT style="font-size: 9pt">&nbsp;</FONT>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="center" valign="top"><FONT style="font-size: 9pt"><B>March&nbsp;31, 2012</B></FONT>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><FONT style="font-size: 9pt">&nbsp;</FONT>
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="center" valign="top"><FONT style="font-size: 9pt"><B>December&nbsp;31, 2011</B></FONT>
</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">
&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><FONT style="font-size: 9pt">&nbsp;</FONT>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="center" valign="top"><FONT style="font-size: 9pt"><B>(unaudited)</B></FONT>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><FONT style="font-size: 9pt">&nbsp;</FONT>
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="center" valign="top"><FONT style="font-size: 9pt"><B>(unaudited)</B></FONT>
</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><FONT style="font-size: 9pt"><B>ASSETS:</B></FONT>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top"><FONT style="font-size: 9pt">&nbsp;</FONT></TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><FONT style="font-size: 9pt"><B>&nbsp;</B></FONT>
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top"><FONT style="font-size: 9pt">&nbsp;</FONT></TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><FONT style="font-size: 9pt">Current Assets:</FONT>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top"><FONT style="font-size: 9pt">&nbsp;</FONT></TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><FONT style="font-size: 9pt"><B>&nbsp;</B></FONT>
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top"><FONT style="font-size: 9pt">&nbsp;</FONT></TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><FONT style="font-size: 9pt">Cash &#038; cash equivalents</FONT>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top"><FONT style="font-size: 9pt">$</FONT></TD>
    <TD align="right" valign="top"><FONT style="font-size: 9pt">9,454</FONT></TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><FONT style="font-size: 9pt">&nbsp;</FONT>
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top"><FONT style="font-size: 9pt">$</FONT></TD>
    <TD align="right" valign="top"><FONT style="font-size: 9pt">13,311</FONT></TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><FONT style="font-size: 9pt">Marketable securities</FONT>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top"><FONT style="font-size: 9pt">2,148</FONT></TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><FONT style="font-size: 9pt">&nbsp;</FONT>
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top"><FONT style="font-size: 9pt">3,281</FONT></TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><FONT style="font-size: 9pt">Other current assets</FONT>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top"><FONT style="font-size: 9pt">735</FONT></TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><FONT style="font-size: 9pt">&nbsp;</FONT>
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top"><FONT style="font-size: 9pt">796</FONT></TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">
&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><FONT style="font-size: 9pt">Total current assets</FONT>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top"><FONT style="font-size: 9pt">12,337</FONT></TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><FONT style="font-size: 9pt">&nbsp;</FONT>
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top"><FONT style="font-size: 9pt">17,388</FONT></TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><FONT style="font-size: 9pt">&nbsp;</FONT>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top"><FONT style="font-size: 9pt">&nbsp;</FONT></TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><FONT style="font-size: 9pt">&nbsp;</FONT>
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top"><FONT style="font-size: 9pt">&nbsp;</FONT></TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><FONT style="font-size: 9pt">Property, plant and equipment, net</FONT>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top"><FONT style="font-size: 9pt">1,855</FONT></TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><FONT style="font-size: 9pt">&nbsp;</FONT>
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top"><FONT style="font-size: 9pt">2,055</FONT></TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><FONT style="font-size: 9pt">Goodwill and other intangible assets, net</FONT>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top"><FONT style="font-size: 9pt">3,944</FONT></TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><FONT style="font-size: 9pt">&nbsp;</FONT>
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top"><FONT style="font-size: 9pt">3,906</FONT></TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><FONT style="font-size: 9pt">Other assets, non-current</FONT>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top"><FONT style="font-size: 9pt">1,808</FONT></TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><FONT style="font-size: 9pt">&nbsp;</FONT>
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top"><FONT style="font-size: 9pt">1,856</FONT></TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">
&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><FONT style="font-size: 9pt">Total assets</FONT>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top"><FONT style="font-size: 9pt">$</FONT></TD>
    <TD align="right" valign="top"><FONT style="font-size: 9pt">19,944</FONT></TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><FONT style="font-size: 9pt">&nbsp;</FONT>
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top"><FONT style="font-size: 9pt">$</FONT></TD>
    <TD align="right" valign="top"><FONT style="font-size: 9pt">25,205</FONT></TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">
&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><FONT style="font-size: 9pt"><B>&nbsp;</B></FONT>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top"><FONT style="font-size: 9pt"></FONT></TD>
    <TD align="right" valign="top"><FONT style="font-size: 9pt"><B>&nbsp;</B></FONT></TD>
    <TD nowrap valign="top"><FONT style="font-size: 9pt"></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><FONT style="font-size: 9pt"><B>&nbsp;</B></FONT>
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top"><FONT style="font-size: 9pt"></FONT></TD>
    <TD align="right" valign="top"><FONT style="font-size: 9pt"><B>&nbsp;</B></FONT></TD>
    <TD nowrap valign="top"><FONT style="font-size: 9pt"></FONT></TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><FONT style="font-size: 9pt"><B>LIABILITIES AND STOCKHOLDERS&#146; EQUITY:</B></FONT>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top"><FONT style="font-size: 9pt">&nbsp;</FONT></TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><FONT style="font-size: 9pt"><B>&nbsp;</B></FONT>
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top"><FONT style="font-size: 9pt">&nbsp;</FONT></TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><FONT style="font-size: 9pt">Current liabilities</FONT>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top"><FONT style="font-size: 9pt">4,547</FONT></TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><FONT style="font-size: 9pt">&nbsp;</FONT>
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top"><FONT style="font-size: 9pt">5,653</FONT></TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><FONT style="font-size: 9pt">Fair value of warrant liability</FONT>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top"><FONT style="font-size: 9pt">11,023</FONT></TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><FONT style="font-size: 9pt">&nbsp;</FONT>
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top"><FONT style="font-size: 9pt">6,042</FONT></TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><FONT style="font-size: 9pt">Other non-current liabilities</FONT>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top"><FONT style="font-size: 9pt">2,368</FONT></TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><FONT style="font-size: 9pt">&nbsp;</FONT>
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top"><FONT style="font-size: 9pt">2,785</FONT></TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><FONT style="font-size: 9pt">Stockholders&#146; equity</FONT>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top"><FONT style="font-size: 9pt">2,006</FONT></TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><FONT style="font-size: 9pt">&nbsp;</FONT>
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top"><FONT style="font-size: 9pt">10,725</FONT></TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><FONT style="font-size: 9pt">Total liabilities and stockholders&#146; equity</FONT>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top"><FONT style="font-size: 9pt">$</FONT></TD>
    <TD align="right" valign="top"><FONT style="font-size: 9pt">19,944</FONT></TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><FONT style="font-size: 9pt">&nbsp;</FONT>
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top"><FONT style="font-size: 9pt">$</FONT></TD>
    <TD align="right" valign="top"><FONT style="font-size: 9pt">25,205</FONT></TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">
&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 9pt"><FONT style="font-size: 10pt"># # # #</FONT>




<P align="center" style="font-size: 10pt; display: none">2




<!-- v.121908 -->
</BODY>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>e36190-121311440541954ccf_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 e36190-121311440541954ccf_1.jpg
M_]C_X``02D9)1@`!`0```0`!``#_VP!#``$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_
MVP!#`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_P``1"`!3`:`#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#^_BB@\>I^
ME(#F@!:**3.#CGGOV^GUH`6BD!SG@\>O?Z4M`!1110`444$XY-`!1110`44=
M\<_7M_\`KHH`****`"BBC^E`!129!_SZTOKUX_SQ0`44#GU'UH'/J/K0`444
M4``SWZ^U<[XJ\6>&O!6B7GB/Q9K6G:!HFG(9;O4=3NHK6VB`!*KOD9=\LA^6
M*%`TLSD)$CN0*Y?XL?%3PA\'/!.J^.?&FH"RTK3(\10H`]YJ=_)E;/2].M\@
MW%[>S8CB082-=T]P\5O%+*G\XO[0'[2'Q#_:.\4I<:W/<6WA^WO'C\*^"K!I
M'L[$32^7`TD4?.I:S.K1Q27<B-(3^YM4BB9D?\@\4O%S*?#G"T\-"DLTXBQL
M&\!E-.3]U/W8XC&.%YTZ/-I"$5[2O).$++FG'Y+BCBS"<.48P4?K68UT_J^$
MB]NBJ5FKRC"[]V*7-4::C9)R7Z)_&?\`X*>Z5IUU<:-\%?"ZZ\8UDCD\6^*1
M-9Z<9`Q`?2=&MW6^NXMI#1W6H7&G?O`R_P!GS1;97^"O%?[;7[3'BV24W'Q,
MU/0[>0MBS\,P6>B1)D$`1SVT'V\85CM(O,@X888*P^E/V=O^"<?B?QO:VGBO
MXR7EYX+T&X$4]AX5L3'_`,)/J$#*KK-J4LB/!HEO(K!8[<K/J+8<S166V,S?
MJK\//V8O@7\+XH/^$5^''AN*_MT`&N:E80ZUKTC8.]SJ^J)=7D1D/S-%;200
M=`L2JJ@?C&!X5\=O$^,<SSWB2KP=D^*2J4,#1G7P=3V,[.')E^#E3KN+C;_?
M<3"4E:5KL^-P^5\=<3)8K'9E+)<)52E3HTW4HU.1V<>6A1<)V:?_`"_JQD][
M,_G:A^+?[26H(UU:_$SXWW<1R[3VGC#QS)!AUW\&#4/*C7;\RA=JJIXP"*UM
M$_:F_:0\)SJ+/XN^//-@*;K?7]4GUWT8+-%X@74&PZD<\.000P8*1_4`+2R"
MX6UME`Q@"&(#H!R`O3L?I[5ROBCX<^`O&]BVG^,/!WA?Q-98.+?6]#TW4XD/
M4/&MW;3>5(C?,DL>V1&"NC*RJ1Z\OH[<5X6"KY;XJ9Q3QT%>$ITL=0A*>CLJ
MM+-9U*:>C;4)][/0[)^'V;4XJ>'XKQZK+5.4:\(R>C7O1QDG%7U>DC\7OAC_
M`,%.OB;H-Q;6OQ,\-:3XUTG>B7&H:21H>OQ1%P&FB7$^F7LB1DL+>2&R\]E"
M_:[<,6'ZS?!O]H?X5_'72_[0\!^(H;B]BA26_P##VHA+'Q!I188*WFG-([;5
M;Y3<6LEQ:,<>7<.&0M\A_&/_`()K?"_Q9;7FI?"R\N/AYKY626WTZ26YU3PO
M<S[2RP2V\\DE_I\<KX0S6EQ*ENK;TL9E3R7_`!W\9>!_BS^SMXW?2]:77O!'
MBFR6Y%AK6CWUY8)?V<RM:RW6BZU9-`UU97,,C12>5(K>7*8KF&-F,8\:IQIX
MQ>#F(I1XWPZXNX9G-4XYG3J>TG![14<>J4:M*H[*U/'TG[350G?WEQRSKB_@
M^<%GE-9OEDI*"Q4)<TXO1*U?E4HR?2&(C[VO*[ZG[S_'G]N#X1?!)KO1H[IO
M''C:#?&/#/AV>$Q6EPO&S6]7?S+72U4@K)&D5[?*Q`%BV'*?EMX^_P""C?[0
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M_:,\3W>Y?BS\5;RZ8Y\G1/%'B&RSYGR@"TT2XM8L9`VJL6-Q)`RS$M_X7;^T
MAX>N(KF[^*7QBL'&PK_:_BSQ:\+9D.PFWU6]FMY0QC9<-&RLJNAR-RU_4#I'
MACPUX>LHM.T/0=&T?3X,+#9:9IEE8VL6`%Q';VL$4,?RJ!\J#@`=`*NS:;IU
MQ&\-Q8V5Q$ZD2)+:P2*Z$$%"CHRLI[@@@@]*]Z/T<N))4_:U?%3.?KLO?<UA
M\9*"J63^.6;*K*TE\?NNVO+?0]!>'N9\O-+BO'^V>O-R5FE+3J\9=Z]=[=-=
M/YZ/`?[?G[1OA::!=1\46/C.RC9=UIXETRVD>1,?ZO[;IJV%T!ZN7>0]2Q-?
M;5C_`,%,-&NO"1FD^'&IIXZW^2NGIJEK_P`(N490!??VH5_M-=KG)T\Z46("
MHNH_,TL?U/\`$;]C7]G[XD1W$MUX%TSPWK$RL5UOPC#%X>O5D?)\Z>WT](M/
MO7+-N=[VSGE<#;YB@FOA6;_@FWXTM/'EOI^F^,M*F^'\PDN7\174,BZ_9)&Z
M?\2Z714VV]U=3*V(+R&]2U*K-+<0V[K#;7//+ASZ0/!$HX7*\_GQ7E^+FL-"
MM*:QE?"N;Y8U:D,Q7M\.XVUJ*K7HP3U9B\NX_P`D:I87'O-\-5:I1G)JK4HN
M5DIR6)?/3L]>;GG"*M=G-ZG^V?\`&_Q;<2&VUJR\+VDDA,=KH5A`KQQD#Y#=
M7ZWD[@9^^2KYSR*TO#OQ)^*^N3+,?&OCF\=F&\6VMZV(_O9(,-I<+"N`PSM0
M$#:#\H45^@OPX_9&^#/P\@MF_P"$=B\5:M"%+ZKXH":FQE4`[X=.D7^RX"'`
M=&6T,L9'RS5])6VG6%G"EO:V=K;P1@+'%!;PQ1QH.BHB(JJ!Z``>U?:9/X9<
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M*^]E?UZGLK97WZA1113`****`"BBD)`&3TH`6BDW+ZC\Z,@<]O7K_*@#YT_:
MG_:E^$/['?P;\2?&_P"-FO-HOA'0/+M;6ULHDN]=\2Z]=QS/I?ACPWITDUNN
MHZ[JS6\JVMNT]O;Q117%Y>W-K8VMS<P_QJ?M%?\`!R7^V%\0->U&+]G_`,.^
M"/@9X,\^5-*:]TBU\>>-GM5D_P!'FU#5-:C_`.$?BN9(P?M$%IX?D@5F`BE;
M89)>V_X.;OC3XE\1?M/?"/X&C4;R+P9\-_AJ/%ZZ,DTZ6-YXL\<:E<QW6L74
M`V075U:Z+HVFZ?82N)WL(I-22V>#^TKY)=#_`(-^/^";O[._[4FE?$S]HG]H
M'P]8?$ZW^'7C>R\$>#_ACK3BX\)+J2Z-8:_>^)/%NC)*$\0HZ:C;6.EZ'K"2
MZ&Z0W]QJ%AJ7F6@M?Z<X-X0X,X5\/Z?B%QCESSRMB^2IA,%*"JT*<*U9T,)1
MCAYRC0J5:THNI4JXARA3@^5*Z][^>N*>)^*N).-)\$\,8Y932PTITZ^*C-TJ
ME25*E&KB*TJT8RJQITT^2G"CRRG)-MM/3\^]*_X+L_\`!4O3[V*ZG_:<EUB*
M,G=I^J?"WX-K9S9(.7_LSX?Z=>8P#CR[R/()R<\C^C/_`((J?\%8/VI?V]OB
M?X[^%/QG\">!+O1O`'P[;QEJ7Q2\*6E_X?GAU2;7=(T70_#E_H;7.I:=/=Z]
M#=:QJ,$]M)8JD6@:B^P@PP5^P'B3_@GS^PMXMT27P]KO[('[-MQI<L)A6.S^
M#'P_TF[M5\OR0^FZII&@6.J:5<)$QCBNM-O;2YB1B(Y5K$_9#_X)\?LT_L-:
MG\5;W]G3POJOA.S^+FI>'[_7='U#Q!JGB2UTJ+PS;ZG#I>F:'?:Y/?:W%I<,
MFLZE<B#4M4U.83W;E;@1".)/E.)^//#C/N'LQPN!X!PV29Y*-..78G"T,'2H
MT[U::J59U<&L--5(4N=PISH5:<VO>DFT?1<.\&<>9-G6`Q&,XPK9GE,92EC\
M/6KXFK4FO9RY81ABO;KEE/E3G"K":O=*QZ#^V=\=-:_9D_99^.?Q^\.Z+IGB
M36_A3X`U;Q?IF@ZU+=P:5JEWIQB\NUOIK%X[N.WD\P[VMW608&UA7\F__$4=
M^TE_T;/\$?\`P?>._P#Y8U_8-\?/@IX0_:-^#?Q%^!OC^76(?!GQ.\,WWA3Q
M'+X?O(-/UI-,U#9Y[:;>W-G?P6UT/+'ERRV5RJ\YB:OQ1_XAJ_\`@GI_T'/V
MB/\`PY'AK_YWU>'P!FOAGE^`QU/CG(\7FF-J8N,\%5PZKN-+"^QA&5.7LL=A
M5S>U4I:QF[/270]?C;+O$#&X[!SX/S6C@,%#"N.*A4G0CSXCVTFII5,/6=E3
MY5I**TVW9^4__$4=^TE_T;/\$?\`P?>._P#Y8T?\11W[27_1L_P1_P#!]X[_
M`/EC6#_P6?\`^"1G[+/[`O[,/@#XO_`_4?BK>>*_$WQZ\-?#;48_'/BW2=>T
ME?#VK?#SXH>*+M[>ST_PMHDT>HC4O!^DK#<M=21I;-=Q&W9IDDB^"/\`@C'^
MQ#\'/V^/VH_''P=^-]WXSM/"?AWX#>*OB5I\O@;6K+0=6;Q#HWQ`^%_AFTCN
M;N_T?6X9-..F^,-6,MLMHDKW*VDHN$6%XYOW?`Y'X+YAPACN-:'"=991@)5H
MUXSJ8^.+YJ%2E3FH4EF;A+WJT+7J*ZN^FOXWB\X\5L%Q-A.%*W$2_M3&*@Z3
MBL&\.E7A*<.>J\&K:4Y7]UN^^[/T5'_!T;^TD/\`FV?X)'ZZ]X[_`/EA7[V_
M\$A_^"C/C_\`X*.?#'XM^.OB!\/?!_P]O?AWX\TKPE86/@^]UF]M=0M;_P`/
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MCC7<[N[E41$4%F9B%5022`*_EY_;:_X.1?!WP;^*&N_"_P#9:^&&A_&>'PAJ
M,FD>(/B9XKUO4=,\%ZIJUH3%J=CX/L-(CCU/5['3[H/9'Q%<7EI87]S;W$FD
MVU_I;6>JWG[4?\%+/'6K_#7]@?\`:R\9Z!=W.GZWI/P3\:II5]:$+/:7VIZ;
M)I,$Z-YD901M?9=U;>D>YXU=U"'_`#DOV./V<]2_:Y_:=^#W[.VG:R/#\_Q0
M\4G2KW7WA^UMI&D6&FZAK_B#4HK=G07-U::+I.H3VT#NBSW"1QNZJS,/3\'>
M!.&\^P.?<3\5QE7RK)+TOJO/5ITFX8?ZUB,16="4*TU2HN,:=.G)7E*5U)\J
M.+Q2XPS[)\;DW#_#DE0S#-;5'B%"G.K:==8>C1I*JI4XN=3F=2I.+M%)*VK/
MWK_XBCOVDO\`HV?X(_\`@^\=_P#RQH_XBCOVDO\`HV?X(_\`@^\=_P#RQK]+
M++_@V8_8ABM+:.^^(OQ[N[Q(42YNHO$GABUCN)E7#RI;+X4F$"NP+",2R!0=
MN\]:M?\`$,Y^PMT_X3SX_P"01G_BK/#/&?\`N4/Z_A7T3S[Z.J=O]7,8U>UU
M2S:S\]<P3MZI'@K)?')I7SVC%M)V=;`:7MH[81JZZ_/OK]6_\$A/^"D7Q!_X
M*/?#_P",?C'X@?#SP=\/;OX:^,?#WAK3K3P?>ZU>V^HV^LZ)<:I-<WK:U//)
M'-#+"(HU@*H8R2PW5^P-?!'[!?\`P3P^#'_!/3PKX_\`"/P9UOQQK6G?$7Q!
MI7B/6Y?&^IZ=J=S!>Z1ITNF6R6,FG:5I2Q0-!*S2I*DS&0!E=1E:^]Z_!.*J
MV18CB#,ZW#.'GA<BJ5H/+L/-58SITE0I*:DJU2K43=95)>_.3UT=K)?M/#-'
M.,/D>7T>(*RQ&<0IS6-K1E"2J5'5J.#3IQA!VI."]V*VUUNSSWXK>/\`3_A1
M\+_B#\3=5@:XTWX?^#/$GC&]MEE6!KBV\.Z3=ZK+;K-)E83.MKY0E8$1E]Y5
M@,'^+;1O^#F[]JQ/B/;:MK?PD^$<WPQ?6U>\\'V-MKT.O0^'WN0)(+;Q-)JC
MB34X+0LT5Q-I?V>6Y`\RW$1*U_2U_P`%B?B./A;_`,$U?VM/$(N3;SZO\.8_
M`-FRLZS&Y^)GB+0_AX@M_+#2>:J>)I)MZ`&%(GG+QI$TB_YI%?O'@9P%P]Q/
MDV?8_/\`+*.8?[93P&#E6E5BZ*AAXU:TZ7LYPM)RK4USZM.-E;K^->,'&>=Y
M!FV3X+)<QJX)+"RQ>*C25-^UG*ORTX5.>$KPY(/W=$[N]W:W^MO\/?&VB?$G
MP)X,^(?AJ>.[\/\`CGPOH'BS1;F&19HYM+\0Z7:ZK8R+*@"R*;:ZC(=?E;J`
M`<5V'.!TSGGZ>WO7X<?\&_'[1\WQS_8`\+>"M9NUNO%?[/'B'5/A1>-)*C7-
MQX5@V:]X"NGB3!B@M/#^JKX6M0_S2+X7>9R3+D_N/VR?3FOP'B3)ZO#^?9MD
MM;FYLMQ^(PT9233J4H5'["K;M5HNG47E(_:>'\UIYWDF69K3::QV"H5Y6=U&
MI*"]M"_>G5YX2\XL_&3_`(+$_P#!4#7O^"=?@#X<6OPX\*^'O%WQ6^*VI:S'
MI$/BB:[_`+&\.^'O#\%L=1URZL;&6WN=1GEO;^RLK*!;F*W5OM#W!;;$K?'O
M_!'W_@M)\8_VWOV@=;_9\^/'A#P%IFIW?@77?&O@[Q/X,M=2TDS7/ANYTF/4
M/#U]IMY?:E#.UQIVH7.J6UY'-`8UTVXBD#F2$5^$W_!??]I`?'G_`(*#>.?"
MND7RWG@[]GW1])^$6BM#(S6\WB"RB&M^/[ORV'[N[M_%FJWWABY*?NY8_#%M
M*F0Y8^#_`/!&OXE+\+/^"E_[*.N33I!9^(/'=_\`#B\61E6*X_X6?X6U[P#I
MT+L>FW6O$&EW$.&4M<V\*$E693_3&6>%.2+PBKYCB\KIU.)<3D>)SFEC93J*
MO0G*G+%X6E%*:A&,,-"G&I3<'[TJE[O4_G['^)&;_P#$3*6$P^8U(Y%0S:AE
M<\'&,/85H<\</7FVX.4I3KRG*$E+2*AROO\`Z5WWAR#]#^?^?RJ-CY:.[L%5
M%+%B0%55&226P``.I.,8J3).,8V_K7S/^U]\39?A1^S_`./_`!)92"+6+W3D
M\-:$VX+(NJ^(Y4TN.ZAR<-)IEM<76K!&X=;!E.0<'^.,[S7#Y'E&9YQBW;#Y
M9@L3C:NMKQP]*53E3[S<5%>;1_2&,Q5/!83$XRMI3PU"I6FO*G%RLGW=K+S9
M^+O[<'[1%]\:OBC>Z'I5TX\`>`KV\T?0;>*5C#JFHPR>3JGB"91E'-S-&]MI
M_!,6GQQG"2W-PM?<7[`_[(EEX=TC2_C;\2-+M[KQ+J\/VSP5HM_!YP\.Z9+\
MMOK-S#<1B--:U",&>S**[6&GRPL)8[RXN(;?\UOV3OA*/C3\=/"'A2^1Y=!L
M[E_$OBDX9O,T71"EW/:.>"!JUY]DTIG#JT4=\\Z;FBVG^CSXF_$3P9\$?A?X
MT^)OC2^M-`\#?#7PAK/BG7KV0I!;V.B^'-.FO9DA11\TS16PM[.UA1I9[B2"
MUMXI)I(XV_E'P,X4Q/B1Q5F_B?Q-1EF-:>:O#9%A*L?:TWC6X\DJ=.5[QP5.
M='#X2"5E4;EK**9^5<$99/B#,L;Q5FJ]O+ZS*&"I5/>A&JK/F47=<N'@X4Z,
M=E+WKWBF_$_VO?VTO@%^Q#\,KGXG_'3Q:NCV;I<V_A?PMID/]H>+_'&LQ1[H
MM#\+:*C(]U=2R/"D][=O9Z/I<4HO-7U&PLDDN%_CC_:F_P"#B?\`;'^+NIZE
MIGP"31?V<?`LCRPV,FEV&E^+?B#<V99@LFH>(_$%A>:7874T1"R#1-%MI;5L
M-9WZRK]H;\P_VY/VR?BG^WA^T+XE^+GC>^U.73[R].B?#3P*)Y9M-\$>#HKA
MHM&\/:/I\;-"M[=;_MVLW4,;7&K:Y>7=S*[JT,<7]"__``37_P"#>GPSXF\%
M>%_C7^W.-:DG\26L&MZ)\`-'U*_\//IND3$26!^(^OZ7+:ZS'J6HVVV\D\.^
M'[[3YM-MYK>&_P!6&H&\TZS_`-<,KX)X$\+<APF>^(%.EFN>8R,9T,LE".*A
M3J<D:CPN%P4W&E7G1NE7Q6)M1A-I1E"\.;]QC1HX>"G6]Z3Z63UTT2ZV[_TO
MYW-1_P""AO[>VIWT^H77[:W[5<=Q<R>9)'8?M`?%+2;(-P,0:;I7BFRTZU3C
M'E6MK#%G)V;B2?KOX`_\%R_^"B7P-OK)-1^,MS\:?#%NR"X\-?&.RMO%<UQ$
MNT.%\7^7:^-8YV1=BR7&O7L*EFD:U>1BQ_NA\-_L!_L/>$M$M/#VA?LB_LX6
MVEV<0BCCN/@S\/\`4[J;"JAEOM2U70+W4]2NI%55FO-1O+J[G"KYT\A`-?G5
M^V+_`,$#_P!B[]H?1]7U7X0^%+#]FGXI26LITK6/AQ9M9>`;J\C21K2#6_AO
M#+%X<M;)I"$N+CPK:Z#?^42\CW310JO/A_%CPLS>J\NSG@/#X#+JTO9+&+`Y
M?7=*,FDJE6&'I4L102CJY8:=:<&O=O;F8L30E[LH66RO%-):;Z_CY'JO_!.#
M_@L'\`_V^K.+P9/"?A-^T!8VAFU/X7Z[?0W%IXBB@3?<:M\/-=/E#Q!81H/,
MN],NH++Q!II$OF6-Y80IJL_Z)?&OX$^`_CUX4/A;QQ8O(L%PEYI>KV)2'5](
MNT(S-8W3(^U9X]\%U;NKP7$+D.F]8I(_Y.O^"=W_``;]_';1OCHWQ-_:D\2W
MWPI\,_!SX@K-X)M/AMXH$/C/XC:IX8U"&ZTSQ9HOB/2G:X\(>#;FXBBDM+R5
MK/Q;?JL\<6GZ3"(-1F_LL`P`/2OPSQ5X=X!EF>(ROAW$4L]R''8=2QF"Q$/K
M6#P\JBC)8:EB:E_K4.5J6J<Z$OW;J2DGR^=C\+A,1">'J0AB*%6-JM*I%3IR
M3L[--6:Z]TUT.3\%^#/#7P]\-:5X4\)Z5;:+H&BVJ6ME8VL81551\\TS<--<
M3R;IKBYE9Y9YG:65F=B:_%+_`(*#_P#!=G]GK]C[4]4^&/PMLHOC]\<-/:6T
MU;1]%U(V7@'P/>+E1#XK\5117"ZAJB2Y63P]X<6[N[?RY%U:_P!'D-NESY]_
MP7P_X*.^(?V4_A7H?[._P8\1S:!\:?CAHVHW6M^(M)N#!KO@+X7B:72;S4],
MND_?:7KGBV\34-$T35+=DO\`38-/UK4=.GL=2MM/O(_Y,?V`_P!@OXN?\%"_
MC;_PK7P)>1:%H6DP1Z_\3/B3K4%W?:7X0T*>X,?VB6.'][JGB#6)EF@T+26N
M+;^T;M)I+F]L[.WNKN+]#\,/"K()</?ZW\85(Y9PI@*36!P%*^&IU\/A6J2J
M5)4K5(8;GC[##X>@E5Q$E:,N64%/JPF$I4Z46XQIT*<%&G3C[L8P@K)62LHV
M7+%+\#ZS^+?_``7V_P""D/Q,U"YF\.?%30?@]HTLK&#1?ASX(\,9CA\PO%'+
MK7BS3/$NLO+&-J-/:W=CYRKAXL,ZMXKX0_X+)_\`!2_P9J0U*P_:P\>:OEXC
M-8^+M.\(^+M-N$B+?NFM?$/AV_\`LZ2!V$KV$EG.PVXF#1QE/['?V<O^"&O_
M``3V^`FBV*:W\'=-^.7C%(8EU3QA\96E\70WTRJAD^S>"KJ4^!=.MO-5GB5/
M#\]\(W,-QJ-U&%"^V?%/_@DK_P`$YOBYI$VD:]^R1\'_``UOA,<&I_"[PO:?
M"/5[.49,=Q#?_#8>&'FEC9MVR_2]M9L".Z@N(1Y5?5_\12\(<'4_L_">'M*M
MED;TY8J65Y4ZM2*<4JBI8B4J]525VYUZ\*VBO!O0U^L8=:*E[JT3Y5JKK6SU
M^_MYGPW_`,$5O^"CO[7/[>D?Q#@^-?PU\&#P1\.K.SM7^,WARWU'PY_;'B^_
MDADM_"<>@2&_TO4+Z'2O-U;5)]/NK)-,@DLC<Q!M1L89/WZ`QZ8XQC]>.G7T
MKY^_9A_9G^%'[(OP<\,?`WX-Z--I/@OPPU_/`]]-%>:UJNH:G=R7NHZQKVI1
MV]M_:6K7DL@$]VT*9BB@AC1(88HT^@J_G_BK,,IS3/LPQN1993RC*:M:V"P5
M/F7)1@E%5)Q<IJ%2LTZLZ<'[.FY<D/=BF^.I*,IMPCRQ>R_K:Y^)W_!87_@J
M+\2?^";3_L\)\/?AGX(^(G_"YD^++:M_PF5_KMC_`&/_`,*\/PU%C_9W]B7$
M'F_VA_PG-Y]K^T[MGV*V\G;OERO_``1Z_P""HOQ)_P""DK?M$+\0OAGX(^'?
M_"F!\)3I/_"&W^NWW]L?\+$/Q-%__:/]MW$_E?V?_P`(+9?9/LVS?]NNO.W;
M(MOY??\`!U+_`*_]A/\`ZY?M.?\`H?[/E._X-6?]9^W;_N?LP_\`H7[0M?KS
MX0X<7@0N+/[,I_ZPNLH_VE[;$^TY?]:?J%O9>V^K_P"Z?N?X.WO?'[QU*E3^
MJ.?*N9+?K\2/Z[Z***_`#A"OQ0_X+"_\%1/B3_P3:/[.X^'OPS\$?$3_`(7,
M/BT=7_X3*_UVQ_L?_A79^&?V#^SO[$G@\W^T/^$YO?MGVG=L^PVOD[=\N?VO
MK^1'_@ZE^_\`L)_[O[3O\_V>Z_0/"[)\NS[CO(<IS;"QQF7XN>/6(PTYU*<:
MJI97C:]-.=&=.HN6K2IS]V:UC9W5T]\/&,JL8R5T[W1^GW_!'O\`X*A_$C_@
MI,?VB!\0_AGX(^'?_"F1\)3I'_"&W^O7W]L?\+$_X68+_P#M'^VKB?RO[/\`
M^$&L_L?V;9O^VW7G;MD6W]L*_D1_X-6OO_MV?[O[,7\_VA*_KNI>*.49=D/'
MF?Y3E.&C@\OP=3`+#8:$ZE2-)5<KP.(J)3K3J5'S5JM2;YIRLY65DDD8F,85
MI1BK*T=%YQ04445\`8'EGQK^-'PZ_9Z^%_C'XQ?%?Q!!X9\!^!M(GUG7=4E1
MYY%ABPL-I8VD(:>_U*_N'BL].L+=6GN[R>&",9?(_B&_:[_X.'OVNOC%X@UC
M2OV<KF#]G7X9-+<6VE26FFZ+KOQ,U'3V9DCNM9\0:G;:IIVBWL\6R1K;PU;1
M2:=,S1V^M76P7#_J!_P=`?%WQ#X:^!W[-7P9TNYN[71/BKX_\=>+/$IMBZ17
M]O\`"G2?#%OIFDWTBL%>VEU+XB1:JMJZLLMWHMK<`JUF`WXX?\$%_P!DCX+_
M`+5_[7WB"V^..F:3XN\,?"?X<7/Q#TSX=:U&+C3/&&O#Q)H.AV3ZSI\BFUU?
MP]H2:E->:GI-UOM[Z[GTJ*Z@N;#[9"W]+>&?"?"^4<"X_P`2.*<NCG/L7B98
M/!3IJO1IT<+7^J76'J?N:F(KXM2CSUU*G1IQA-<KYY'?0ITXTG6FN;=VT=DO
M)K6^WW^3/A)O^"CW[?SZO_;;?MI_M._;2V[R4^-GC]-)W$$<:#'KJZ&!SPHT
MX*#@@`JI'[;_`/!(+_@JM_P4&^.'[6WPH_9S\>?$>Q^,'@3Q5+K$_B6Z\:>&
M=*?Q/H7AK0-#OM6O]2L?$V@6NCWLUQ"+1%677CJOF22K&S@NM?V&0_"'X3P:
M*GAR'X8_#V'P]':K91Z'%X,\-QZ/'9A=@LTTQ--6R6U5`%6!8!"%X"8KP3X=
M?L%?LE?!_P"/-U^TC\)_@IX0^&OQ1O\`P=K/@C4;SP/8+X;\.WNDZ[J>BZI?
M7;>#=+^S^&+/73/H<,)UW3-*L=2N;.^U*VOY[Q+E3%Y.=>*_!6>9-FV7S\.\
MOP&+K8.O2RS&488"NZ&*E'EH5IN&$P56A[-MS;HSJ.\5"SC*32EB:4XR3I=/
M=V?;TMM?3T\S^>+_`(.5?V)?'GBJ;X=_MG?#[1KG7]`\)^&S\.?C!9:=')/J
M.@6$>HW&I^$_&C6L2L\VB&2]U'0M=N4(_LJ7^PIVB>UNKZZL_P"?S_@GS_P4
MA^.W_!._Q_JWB+X8OI_B3P+XR_LZ+XB?#'Q#O.@^)X]+>7[!J5I=1?Z9H7B/
M38;J\ALM6L6V2P74MMJEIJ$"6Z0?Z:.IZ9IVM:?>Z1J]A9ZII>I6LUGJ&GZA
M;0WEC>VEPC13VMW:W"207$$T;,DL,R/'(C%64@FOYSOVSO\`@W*_9T^-FL:W
MX]_9L\33?L[>+M5>>]N?!D.FKK7PGNM1EW2,^F:*LMMJ/@Z":4Y>QT6ZGT6W
M&U-.T:PB4HW9X>>*7#BX;CP+Q[@_;91&,J&%QCI2KT%AY5/:PH8JE27MZ<J%
M1N6'Q5!2E!*-_9R@JC_GGCCPYSS^WGQ=P;B/9YE.<:U?#*HJ595HPC"=7#SG
M^ZG&K"*52A5:4O>MS<S2^A_V/O\`@O1^Q)^T]-I?A;QEX@O?V=_B??\`DP1^
M&?B@T4/A?5;R5D0Q>'_B%9JWAV4F5TCAM?$+>&M2NG?;9V5VL4LB_MC:W=K?
M6UO>V5S!=VEW#'<6MU;2QSV]S;S(LD,]O-$S1S0RQLKQR1LR2(RLI*D&O\PC
M]MC_`()T?M/?L%>);32/CCX/C?PMK4\L/A3XG>$YYM:^'_B9XAO>TMM7-M;3
MZ7K,47SW&A:Y::=J80//;PW=CLO9/V)_X($?\%./B+X(^,WA?]BWXN^)=1\6
M?"CXF2S:7\*;S7;V2\O_`(<^-T@GO+/0].N[HM<2>%O%(CEL_P"RWG>/2=86
MQN--C@AO=366N-/!S)Y9%7XNX`S19CEE*E/%5L"ZT<5'ZM37-6G@\5&TW*A%
M.4\/B$ZG+&5JBDE!SPIXIYK#.*/#/&F7_4\PJ588:GC/92P\E7G:-*.)HRO'
MEK2:C&M2?)S->ZXRO'^W:B@?Y^O>BOYQ/WI?U8_G#_X.>_\`DP[X/?\`9W7@
M;_U37QZK\A?^#8K_`)/Z^*W_`&:+X_\`_5Q?`3/Z5^O7_!SW_P`F'?![_L[K
MP-_ZIKX]5^0O_!L5_P`G]?%;_LT7X@?^KB^`E?U+PM_RCQQ/_P!?\R_]2L`?
MSCQ'_P`GRR#_``Y;_P"H^)/[M,8Y`Y)Y^G>G445_+1_1Q^<7_!7+C_@FU^V"
M0#_R2#6LC'4BZL>1]<\5_"/_`,$G/BS\.?@9_P`%!OV<_BK\6?%>F^!_A]X2
MUGQG<>(_%.KBX_L_2H=0^&GC31[)[G[)!=7&VYU/4;*R3RX'/FW,>=J[F']W
M7_!7/_E&U^V!_P!D@UG_`-*K&O\`.L_9C_9U\>?M9?'/P#^SY\,;OPW8^.?B
M-=ZO9:#=>+M0OM*\.Q2Z+X>U?Q-=G4K_`$W2]:O;=&T_1;M(##IET7NF@C<1
MQN\T?]9>!V'P6*\.N-<-F6)>#R^OC<32QF+32>'PT\KH1JUDY*23IP;DKQDK
MK6+6C_FKQ?K8O#\<<*5\#0^LXRCAJ%3"X:U_;UXYA-TZ=DTVYRLM&G;9H_T/
MO^'Q?_!,[_H[SX8_EXF_^9^NN\`_\%3_`/@GY\4?&WA;X<^`/VG_`(>^)_&W
MC?7=-\->%?#VGCQ!]NUK7=6N4L]-TVT^T:)!!]HN[F5(8O.FBCW,-SJ,D?R7
MG_@VA_X*$#D^+_V8_P#PXWCO_P"=17TK^QM_P;^_MP?`/]JW]GCXV>-O$_[/
M=UX0^%GQ=\#>.O$EOX?\>>,K[7)]&\.:[9ZE?QZ397GPUTVUNK][>!Q;07%_
M9PR2E5DN(E)<?&9CP/X.T,OQU?!>(E?$XRC@\35PF'<\-:OB:=&<\/1=L%%V
MJU5"F[-/WGJFKKZ;!<8>*=;&X2CBN"51PM7%8>GB*WLJZ]E0G5A&M5UKM+DI
MN4]4TK']GOK1117X`?MY_.9_P<P_$=_#'[#W@#X?6MR(KKXG?';PXE]`S*&N
MO#W@_P`.^)=>O(UCSN(C\0'PO.SKE4V!6&9$-?R4?L^?LC:S\=OV7/VR/C=H
ML%U/J?[-&B_#+Q?:6ULKN-0T35/$.HZ=X[@D0#RP-'\-N/%3R$^8MOH4\:#$
MQ#?OC_P=*^/A/XL_92^&$<V]=/T+X@>.+F%6R(I-2O=$T.W:1=W#2)ILIC)3
MHC_/GY:]Z_X-R?@1HOC/]AK]JF7Q+817&C?&WQ_K'PRU#[1!',MQHVD^`+.S
MO8PCC+VX;QC)N4_NGFC9>2C;?ZTX4SFKP)X+9=GE)\F(QN?T<0M$Y5L/5S6E
M1Q%**DK/VF!PM=*WV7SQ>S7\R<2Y7'C#Q7Q^4U/>HX;)ZU!:Z0JTLOE5HRNM
MK8FO2OW_``/SZ_X-IOVB8?A]^UIX[^`6M:E]FTGX[^`[J]\-6LC@0W'COX>+
M/KL=M&I90+B]\(R>)Y]_S%O[)BA5=TH-?VD?'OXJZ/\``_X)_%?XP:_.EMI/
MPT^'WBKQK>R2_=,?A_1KO4EB`ZO)/+`D$<2Y>6618T5G8*?\S?P5J_BK]A3]
MNC1=2G6XL?$G[-/[0QM=3AN/,CDFM_!7C&73=8M+D#89;;5='@N[:X4'R[FS
MO'4,8Y<G^N[_`(.'/VJ[7PQ^P1X)^'W@[5D6Y_:I\0>&M\EO<!;F;X::!!8^
M.]2>-H'++%J>J1>%=-N6#B"[T^ZU.R<RQ32QGQ_%+@U9YXC<(XO`Q4\%QI#!
M.M4BO<;PKI_6JG,M^;+Y4JE_[M[VV]3P]XJ>3<"\387%MQQ?#$L5[*,M)VQ2
MFJ$;/56Q:FN7>[::/Y$OV:?A)XK_`&[_`-M;P'\-[B6\GUGX[_%F^U?Q?J:2
M2375CH5Y>:CXP\>ZVTY1V9]+\.VNM7Z/(%\V6".,,K2*:X7PM+>_`/\`:R\/
M2PK+8WWP>_:!TIX!)*Z36TO@;X@P&$O.LBR*\?\`9J-Y@D$F1NW;J_H(_P"#
M8G]GL^(?C1\;_P!I35+%9;+X=>$+3X;>%[J:+>L7B#QO<1ZGK<UJ77"W5OH>
MB16C3Q-YD5KJ]Q`Y6.[(?\=/^"K7PZD^$W_!1C]KGPDL<EJG_"WM5\8V$>)$
M,&G?$:QTWXC:4D18^88XM/\`%-JD,FXM(BK)N.[<?VC!\24LSXYXBX$I2C]0
MRWA?#4HPBHV5>3=/%[6>F'QF%IV6D7![.U_RG$Y%5P'".2<7U(MXK'<0UZGM
M'?FE1ARSP[3_`+U;#XB6O5]3_30TF_M]5TO3M4M&WVNI6-I?VSY!WP7D$=Q"
M^02#NCD5N"1SU/6OS&_X*FZW/:_"_P"'NA(7$&K^,Y[V9<+L+Z1I5PL6_)SD
M?V@Y0#C.<\XKZH_8I\?K\5?V0_V:OB$LPF_X2WX)?#;5WD^4L9Y_"FEBY60*
MD866.=)(ID*(Z2HZ.JNI`^0/^"JL$K>"OA3.J,8H?$^M1RR`_*C2Z7$8P1GJ
M_E/@@$@*>1QG_+#QYIUL!X=<<X>*<:E##5<+46MU&.,IT:L7MIRJ2=[:75C^
MJ^)L0J_!>-Q5*5XXC+:%6+[PK*C)[='&3O\`/6QYW_P2J\-QS:_\5?%CINEL
M--T'0XF*@^7_`&A->WDNUMOR,XL4!`<;E494XR/"O^#D?XPZGX$_8=\._#33
M+I[,_&KXJZ#HNM>5-Y;7?AWP=!-XPNK`JKJ[QSZW8^'KB;;N39:&*12LV:^H
M/^"4EQ$-*^,UJ6_?/J7@Z=4]8TM-=1F].&=1Z\U^>O\`P=!Z+?W?[/7[-NN0
MQLUAH_Q>\16E])\^R*75?"!^QYPA0-(;&X`+NA(4A`V&Q])]"[!8265^&$)4
MX2C7S7%XJM%I6EB:>/QLH.2ZM.A12YKWLD]#I\.:=./#F4.*2<OK%25K:S^L
M54[[W=HK?6R78_%S_@@E^R[X;_:-_;JT+7?'&DP:YX.^`WAZY^*UQI%Y$L^G
MZAXKLKRVTWP,FH0L"LMOINO72>(TB;,<]YH5K!<1RVLL\3_Z$@&W`4`+_+V'
M/T[5_$7_`,&Q'BK2-+_:E^/7A:[N%CU;Q7\&-/N=(@9@#<1>'/%UE<:EL!Y8
MQ1ZC;L0.0I)/`)']NU?TEX^XS&8CC_$8;$.:P^!R_`TL#!OW%2JTO;U:D([)
MU*\ZD9O>7LUK9*WVF,;=:U]%%67:^X48[]Z**_%#D"D/0_0TM(>A^A_E0!_F
MK?\`!8+XNZE\9?\`@HM^TQX@O+Q[NR\->,U^''AY/-\R"TT'P!I]KX<M8+50
MS101SW5I>ZE<1Q':^H7][</NGGF=OW^_X(F_M<_\$[/V.?V-=,TKXB_M#_#G
MP;\;/B9XL\0>-?BA8:K#KC:W9/#>2:%X1T*XN;71+E?L.E^&=-L[ZWLX[F2W
M@U/6M9NX@LE_.7_F7_X*#Z%J'AK]N']JO1=4^T?;;/XY_$$RFZ;?.RW6OW=Y
M"SMY<6X&&XC*'8!Y>W!8?,=;X5_\$X/VX_C?X#T'XG?";]F[Q_XZ\`^)XKF;
M0/%&B+HTFF:G%9WEQI]TUNTVK0S`V][:W%K*LL,;I+"ZE>.?[XSKACAW._#K
MAG),USUY#D\,)D]2GB*5?"8>.*E1P-Z6'G+%1=*I&7,\1RQBIN=&-2]HN_LR
MA&=&$)2Y(VAV6R5EJ?WI?\/A_P#@FC_T=W\,?^^?$_\`\SU>O_`__@H5^QE^
MTEXZB^&GP._:`\%?$?QU/I>H:W%X;T(:T+]M*TH0G4;T?;M)L[?R;43Q&7,P
M?]X-JM7\"'_#HG_@I3_T:!\5/^_6@_\`RZK]@O\`@AU^P!^V5^SG^W5I?Q)^
M-_[/OCKX;^!H/A7\0]$E\2Z_'I2Z<FJZM'I`TZR9K34KJ;SKLV\PB`A*_(VY
MEXS^(\3>%OAWE.09MF>6<;RQ^/P6"JXC"8/Z]E-3ZS7A&+A2<*--59<S?PTV
MI.^FQR3P]&,)252[46TKQU=EY_U?T/[.<\XP?KCBEHHK^=3A/Y#O^#J7_7_L
M)_\`7+]IS_T/]GRG?\&K/^L_;M_W/V8?_0OVA:;_`,'4O^O_`&$_^N7[3G_H
M?[/E._X-6?\`6?MV_P"Y^S#_`.A?M"U_4DO^49H_]A"_];4]%?[D_3_VY']=
M]%%%?RV><%?R(_\`!U+]_P#83_W?VG?Y_L]U_7=7\B/_``=2_?\`V$_]W]IW
M^?[/=?J7@M_R<SAC_KYF?_JFS$Z,+_&C\P_X-6OO_MV?[O[,7\_VA*_KNK^1
M'_@U:^_^W9_N_LQ?S_:$K^NZEXT?\G-XH_Z^Y9_ZI<M'B_X\O2/_`*2@HHHK
M\N.8_$S_`(+L?L2^*/VO_P!DFTUKX::-/K_Q6^`GB"[^('AK1+&%[G5/$?AJ
M\TN2P\;^&=*MXPSSZC>6L&DZW96\2//>7?AR"Q@7?=8/\*?[//[0_P`9?V1O
MC'H7Q@^#^O7/@WXA^#[FZM&6\LO.M+ZRG_T?6/#7B71KL1B]TK4(T-KJ>G3B
M&9&59();6]@@N(?]5_KP:_'3]NG_`((G_LE_MI7^H^/+;3[OX*?&B^$LMW\0
MOA];VT=CXENGP4F\;>$)MFC:W<!MQ?6++^Q_$$V\"]U2^@@@MD_>?"[Q4RWA
M[*L1PCQ9@WC>'<54KNG5C26(^K1Q7^\4,1AI?QL)4DY5'[-2J0G.=J<U+W>S
M#XB,(NG45XO9[VOT:[?D?$7[(G_!R7\!?B&VB>$_VKO!>J_!'Q-=""SG\?\`
MAR&Y\5?#&6[**AN=3M;?S?%OAJ"XFX4IIWB&SM=Q>]OK6UC>Y']&W@'XA^!?
MBEX6TOQO\./&'AOQWX0UN`7.D>)O"FL6&NZ+J-NW22UU'3I[BVE`Z,%DW(>&
M4&O\]']O7_@C'^U1^PSI-[\0KV#3/B]\$[:Y$5U\2/`T4XF\-+-(5M/^$U\*
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MVAN)HH9)%DD13T^0>F#^-?P\?\'$VE_M//\`MH>&/B78^`/BCX?^%G@3X;^'
MO#GPY^*OAW3M9'AU]1FO-0UCQ"UMXJT#S+?1M635-1-L]CJ%Y8:M)!##,MNU
MFUO(_P"5?@O_`(*N?\%&/AYIL>A^'/VM?BU#I]J@@AM=>U#3O%;6T:HZ"*"3
MQ;IFM7$"*)&PD<B!7"N`'1&7Y/(_`[,.)>'\ISO)^(<IE5QV&5;%8+$.:>$E
M*<TH.MAGB+S4%!RIU*-.4).2;TL_PK-O&#!Y#G6995F>29@J6#Q+HX?%4>6^
M(A&,;S]E75)6YG)1E"I*,DDUY_V\_P#!;?6/A;I?_!-S]HB'XFR:-NU30=/T
M_P`!6VIM`;RX^(TNL6+>%VT.&1UFDU2UN1+=%K99'@L(KV:=19I<D?PD_P#!
M.K1=>\0?MT_LI:7X:$YUB7XX>`YX#;Q+-(D%CK5O>W\FQ@4$:6%O<F5VPL<>
MY\C;FN2^)7QR_:Y_;7\7Z+9_$3QO\7?V@_%LEZ+;PSX>VZSXIFCO[W$*V_AW
MPIHEJ]G;7-QN\M8=+TN)V5B@7:Q!_K&_X(?_`/!'3QI^S=XFA_:U_:DT4:)\
M5#H=WIWPJ^%]Q/:W-UX"MM=A6+4_%OBLVKSQ1>,+K2C)I.EZ.ERZ:#8:GJSZ
MI$^MRVB:+^HX;"8#P:\/,^RW.<ZPN/SC.8XMX?+\/-M/$8K!QP<*="E+][[*
M"7MJ^(G3I1:TY5:+E^<U\3CO%/CC*,?EF4U\%EN6RPOML96@K^PPV)^LRG6J
MQ7(JDG^[I4XSG)76MMOZ?QP!VZ#\:6BBOXY_K^MC^J4K)+LK'\X?_!SW_P`F
M'?![_L[KP-_ZIKX]5^0O_!L5_P`G]?%;_LT7X@?^KB^`E?KU_P`'/?\`R8=\
M'_\`L[KP-_ZIKX]5^0O_``;$_P#)_7Q6_P"S1?B!_P"KB^`M?U)PLU_Q+QQ0
MKJ_M\R_]2L`?SEQ&O^-XY`^G+EO_`*CXD_NVHZ<FBD(S^?/&<^U?RV?T<?G1
M_P`%;8I;C_@FW^V"L,4LK+\&]>G98T9RL-O-:33RL%!(CAAC>:5S\L<2/(Y"
M*2/X;_\`@C!K^C>&O^"G'[)^J:]J-KI6GMXQ\3Z2+R]E2"W_`+0\0?#CQGH.
MCVIE<A!+?ZOJ5C86X)&^XN8H^K"O]$OX^?"71OCS\$_BI\%O$$K6^C_%#P'X
ME\$WMRB[S:QZ_I=Q8)="/_EH;:::.X\L8\P1%,KG(_S%/VH_V5/CK^Q1\9M=
M^%_Q9\-ZUX6\0>&M4^T^&_%EG'=1Z%XITI)A-HOBWP?XB@5;:]M+R(0W"M:W
M"W^D7RS:9J<%AJUC=VD']/\`@57R_-N&.,>#*V-IX3'YK[6IAU-KGG1Q6"CA
M)5:5.4H^V>'J0BYPB^91FMN:Y_/'C%1QV7<1<+\44L)4Q&#R[V<:LHQDX*M0
MQ:Q$:=2<4_9^UA*T)25G*,EJU9_ZHVY2.V#ZD?RI<CU'YBO\MBU_X*"?MQ6-
MM;6=I^UG\?8+6T@AM;:%/B;XG"16\$:Q0Q)G4"=L<:*B@DG"CDU/_P`/#?VZ
M>_[6_P`?_P#PYOB;_P"3ZXO^);<]OIQ'E+7_`&#XE/\`-]+^G=G8O'K*&E?(
M\QB^O[ZBTMM$[*_76ROIL?ZD.<]**_FY_P"#<'X\?&?X[?!W]I75/C-\4?''
MQ0U'0/B7X.L-%OO&_B+4?$5UI5E=>%KRYN;2QEU&>=K:">=5FECB*J\@#L"<
M5_2*>A^AK\,XGR"OPOG^99!B*]+$U\MK0HU*]%2C2J.=&E63@I^\DE52UZI]
M#]@X=SNEQ%DN!SJC1J8>ECJ<ZD*-5J52"A5J4FI..C;=-O3HUU/X`_\`@XW^
M(2^+O^"BVH^$H9P\/PK^$?PZ\+W$(.1!JFN6M_X\N&;*KM>;3/%FC94%UV1Q
MON#.RK_4/_P0N^&;_#3_`()D_LZI<VS6^I^.K?QI\2M2++(AG3QCXWU^]\/7
M"K(<[9/"$7AS#H!'+M\Z/*R!F_A\_P""FGQ$N/C%_P`%"/VM?%T3F]%[\<?%
MOA72'CE%P;O2?`UZGP^\//"ZR.K)/I/AK3S"J.45&1$(4`#_`$>_V5/`<7PN
M_9E_9]^',$:10^"/@S\-?#"1HH4#^QO!^CV#$X51N9H&9SM!9B6;DFOWCQ6M
MDWA;X<\.I<DZU'#XRO"_O>TP^7QE73B[M*6)S"4]])1M=W/QGPV7]J^(G&^=
MN\HTJF(P]*35TH5\9RTK2[QHX3E7DS^*/_@XZ_9R@^%'[;>G?&/1;`6F@?M$
M^"--\1:@8(=EL/'/@V&V\)>(&'ECRHI=0TFT\-ZG,#MFN[^YU.]D#R2R2'\K
M?VF?VOO'/[3?@+]EOP3XN:Y\K]F[X*0?">VEEG,L>KW%EXDUI[37`"2XGD\%
MP^"M'O7F+RS:CHU]=[A'=(H_LT_X.*?V:Y/C)^PU)\6-$L/M7BG]G#Q;IOCB
M0Q1>9=3^!=>DB\+>,X(\8*QZ>;_1O$UU(S%8M.\/WY",[J5_B<_9"^".I?M(
M?M/_``)^!VF6TES)\1_B5X9T+4!&AD^S>'UOX[_Q/J,J#DVNE>'+/5=3O&'*
M6MI,XY`%?IWA3GF69MX?Y5F^:*G4QO!$,PPWUB;7M<-2P^#J0A*+Z*IEM6G2
MY7I)TXR=Y137Y[XBY1CLMXTS'+,#ST\-Q3+!5E2@FH5IUL13DU):ZPQD95'9
M:<UEI<_OO_X(D?LW+^S?_P`$]?@U9ZC8"Q\9?%J"]^-'C7<KK.U]X[:.X\,V
MDZRA98)M+\!VOA33KJU/RPZE;W[*H,SY_F+_`.#DOX;Q^$O^"@&E^-K:W\NW
M^*WP2\$:Y?3[0OVC7O#-_K_@NZ&54>9Y.A:)X:7S&=G&[R\*D<>?[R]$T?3_
M``_HNDZ!I5NEII>B:;8Z3IMK']RVL=-MHK2T@3K\L5O#&@]A7\D'_!TK\/V*
M_LG?%)(3A&^(G@.YF16*YF&A:_;)*P.!Q!<&'>.?WP0_?%?AOA/Q)6QOBZLT
MQ-3EGQ%5S>%9-JW^U0GBZ-)<SORPJ8>C"FKW2A%7:N?K_B3D-/!^&4<!AX)K
M)*>62IV6MZ,J>'JU';>3C5JSF^K;;/UD_P"""?Q,3XC?\$R?@;:2W`N-4^'&
MI_$/X;:L0Q;R6T3QQK>J:%;D-)(Z&'PAKOAM-K%0<;XT2%XE'TC_`,%(O!\_
MB/\`9UNM;M(6EN/!7B;0]=F$<9ED_LVYF?0[PA5!<)$^K6]W<2*"(K>VEE<"
M-'=/QQ_X-=_B!_:'[/7[2'PP>?#>%?B]HGC2U@9C@Q^-?"-GI%Y(BXP`)/!5
MJLC`@DN@QQFOZ9/&WA73O''A'Q-X0U:)9=.\2Z%J>AWJ.`5:WU*SFM9".I#(
M)"ZL,,K*&4@@$?CWCYPHLSS+Q(X8LH_VI/-/8?RJ>84_KV&:OLE.M#5;6=MC
MZ+A9+B'PYRR@Y-O$Y(L%=[JKAH2PJ;OL_:44W?HS\/?^"8_CFVT#XSZ_X.O+
MA(4\;^&9CIRR.%6;5-`<ZAY,0/WYY-/>_F`_YY6LI'H?LK_@J_\`LEWG[97[
M$?Q8^%OAV*)_B!H=O:?$CX:^:JG[1XS\$&;4;?1E9L")_%.CMK'A6.X9ECM9
M=:BO)LQV[*?QGNX/&'[/7QD>-'ET_P`6_#+Q>KPOAD6=M.NEEA<KA?-L-7L"
MI*Y,%WI]V5)>"8[OZ:/@[\4_#OQF^'GA[Q[X;N8I;76;-3=VHD#7&EZG#^YU
M+2[M.&CN;.Z22/#JOFQ>5<Q[X)HI'_ESZ*W'.(R>C6X7JU/JG$?!N<SS#!T*
MWNSE0CB8RJTU!V;6'Q<*D*T4KJ%9-[W.;PTS;EPN(R2N_9X[*\14G"G+23HR
MG::47K>E54E-:M<ZO8_S&/V2OVD?B!^Q7^TM\/?CIX3MYH?$/PX\220>(O#6
MH++:KKWAV[\[1?&?@_58)`KP'5-(GO[%7EC,NEZF+34H8Q>6$!7_`$KOV7/V
MHOA#^UY\'?"WQH^#?B:RU[P[XBLU:]T\7$`USPKK<0":GX9\3Z8KFYTC6M,N
M0T4EO=1H+JW-OJ5DUQIU[:7,W\UW_!9S_@B=XE\6^)_%?[6O['?A6;6]4UI9
M]?\`B_\`!?1Q#]OO-3A3?J7C7X=Z=^Z-]>:A"AOM>\(VC2W]_J,=UJ'A^WN[
M[43I9_F/^`_[3?[2?['WCFZ\1_!'XC^,OA)XLMKD6VMZ=;JHLKV6S<JVG^*?
M"&O6EYHNK+`X9)++7-(N?*(*F-&''^JN?Y!D/CGDF`X@X?Q^'P'$V!P\</B\
M-B&GRZ<[P>.A33JPA"K*4L+C(0J0<)M<DN?W/U^=.&+@IP:C-+K^,9+R?5?B
M?ZI?Y]:IWVHV&F65UJ.I7EKI^GV,$MU>WU[/%:VEI;0(9)KBYN9VCA@@BC5G
MDEE=(XU!9V`&:_AD\-_\'-'[<6DZ+;:?KWPN_9O\5:G;1B)]?N/#'Q!TB[O@
ML:*+C4++2_B1%I9NWD$DLS:;:Z79LK)'#8P;"TGYZ?M:?\%:/VWOVRK"\\-_
M$_XH1>'/AY?#;/\`#'X7Z9_PA?@NX0N7,>I;+O4?$WB"%LJGV;Q)XEUFU1(U
M\J&-FF:7\RRWZ/G&^)QBHYC/+,MP<9I5<9]:6*<J:=G+#T*45.<FM8QK/#IZ
M7DG=+G6"J-ZRBEWU?;;3UWML?Z!?[.O[:O[,7[5U[XZTSX"_%SPSX^U3X<>(
MK_PUXKTK3YIK;4K6XL9VA36+"TOHK:76_"NI;2^D>*]&6_\`#^H%9K>'4#>V
MMY:V_P!3U_`K_P`$7O\`@G)^UG\9?C-X,_:+\-^(OB#^SC\'/!>M6=Y=?%73
MH9M$UWX@VEI=02ZEX2\`V>JV[67B+3=4@2;3-7UZ^TW6/"%@YGMKFVU>_M9]
M)']]*\`9]*^%\1>%\FX2SYY5DN>0SFG&C"6(5HNM@:ZY5/#UZM->PJ3EK-*G
M:5*+4*L5*SEE7IQI248RYM-?)^=N^_D?PB_\'%W[)6L?"/\`:VM/VD-'TUS\
M._VBM'L);R\@3_1M(^)WA/3;71?$&F7.S/E'7-'M=&\26DTV/MM[<Z^D'R:>
MRK]2_P#!O1_P4H\(^`=.NOV'?C=XGTWPWIVJ>)+[Q!\!O$^OWT5AI@U;Q"Z3
M:[\,[B^N6BL[234]7677?"8N)4EU#6M8U?2(Y);BYTBSK^H/]K']E?X3?MD_
M!+Q9\#?C#H\E_P"'?$EJ7T[5;$QP>(/"'B*W61M'\6>&[Z2.9;/6-'NB)X1-
M#/87T/G:;JMG?:7=W=G-_GP_MY_\$NOVFOV"?%=U)XP\,ZAXP^$ES?3+X2^-
M/A.QN+OPQ?0)(6M;;Q&+;SY_!GB$0[';3=;-O#=N)GT6^U.*VN9(/VS@C/.'
M?$G@6GX=\2XV&7YSE\*=+*<55E",JT<*G'`U\,ZC4)XBA2?U:OAW+GKT>:47
M><N3KHU*=>C[&H[2226RVV:OUMOUOZW/]*]75U#(P96`964@@@C(((Z@CD'H
M1R*"2#TX]?\`)Z>OXU_G&?LV_P#!;'_@H+^S-H^G^%M`^*NG_$WP9I<<<.F^
M$_C/H*^-K.QAB"JEO;>(K:]T/QW!:)&@BCL$\6K8PIGR+:&0^97NOQ3_`.#B
MC_@HS\1M&FT?0-3^#GP;-Q";>?5_A=\.[U]9:)Q*LIANOB7XI^)$-E-(DBH+
MK3[:TNK?RHY;.:VN`TS_`!V(^CSQQ3QOU?#ULGQ&$<GR8YXRI2@H75G6H.A*
MM&;3OR4XUHJW\3JL7@JM[*46NCU7;=:^>U_U/]`#.>E%?S\_\$)?^"ENM?M>
M?"_7?@7\;/$5YKG[0/PDB;5%\3:O,9K[XD>`-1O&6UUFXN&.9O$7AR]F&DZW
M&0IN;"32=3@$ADU%;3^@:OR+B+(,PX8SG'9'F<(QQ>!J\DY0;=*K"45.E7HR
M:3E2K4Y1G!M*5G:2C)-+FJ0E3DX2W1_(?_P=2_Z[]A/_`*Y_M-_3[_[/O^?S
MKD?^#6[QYX0T3QG^V-X#U;7]-T[Q9XST3X$Z[X8T6\NHK>\UK3/!EW\7[3Q+
M/I\<KH;IM*F\8^'OM$,.^58[\3;/+CD9?UG_`."Y7[`?C;]MS]G'PSK/PCTO
M^WOC%\"-9UOQ1X5\-QRP0WGBSP[XAL;*V\8^&=+ENI8+;^UKL:-HFJ:;!)-&
M;V[T:*PB<2W2*_\``5<6_COX7^*;BVNX?%WP[\:Z#=7%G=VUQ'K/A'Q1HM["
MS075I<0R+I^K:==1,KPW%O*L,J,&CD0$$5_4?A[@<LX]\'9\$4\TIX/,*%?$
M1Q*:C4JX>2SJ6;X6L\.YPG5H5$X0<HRBKJI%2YHGH45&KAO9*5I;/NE=.]NO
M;[C_`%J\CU'YBC(]1^8K_*#_`.&@?CQ_T6_XN_\`AR_&?_R[H_X:!^/'_1;_
M`(N_^'+\9_\`R[KY[_B6G,O^BLP'_AMK_P#S5Z_TM8^HO_GY_P"2_P#!]?Z6
MO^KYD=N?ISCZU_(E_P`'4OW_`-A/_=_:=_G^SW7ZJ_\`!!#Q-XC\7?\`!-OX
M8ZWXJ\0:WXGUF?QQ\68I]7\0ZM?ZUJ<T5OX\UB*WCEU#4KBYNI(X(E6*%'E*
MQ1JJ(%4`#F_^"Z?[!/C+]M3]FKPWK_PET>;Q#\8O@)K6M^*_"_ANT`?4O%GA
MCQ!I]E:^-?#&CQ,Z+/K%W_8OA_5]-M4W7&H7.A+IEJCW-[$C?G'!#PG!/BQ@
M,/FF,I_5LFSG,LJQ&.Y?947*6'QN6PQ$E*4O94G6JPE-RD_9P;<G9-F%*U+$
M*,G=1DXWVUVON?DA_P`&NGQ,\&>'/'_[77PVUS7=.TOQ9X_\/?!;Q'X4TR^O
M(;6?6K'P#??%*R\2+IRS,@N[FQ;QUH4TEM"S7'V:66X6)X8)WB_LKR/4?F*_
MR2Y(_%W@#Q%)%*GB3P3XMT.ZFMY8I%U/PWXBTB]A=X+B"1&^Q:E8743I)#-&
MPBE1E>-U!#+7<?\`#0/QX_Z+?\7?_#E^,_\`Y=U^[\=>"%3C+B3&\2X'B+#8
M2&9PPLZE"KA)XF*G0PM#"QG2K4L1",J=2E0A*W+HVVFTSKK87VLW/GM=+2U]
MDD?ZOF1ZC\Q0"#T-?Y0?_#0/QX_Z+?\`%W_PY?C/_P"7=?WI?\$`O$_B7Q?_
M`,$Y/!.M>+/$.N^*-8E^)7Q5@DU;Q%JVH:WJ<D%OXGD2WA>_U.XN;IXH8_DA
MC:4I&GRH`.*_%N/_``?Q?`62T<YKYYA<RA5Q]'`*A1PE6A)2K4<1651SG6J+
MEC]7:<>6[YUKH[\M;#>QAS\_-JE:UMUZ^1^Q6O\`BWPMX4&E'Q1XDT'PX-=U
M2'0]$.NZOI^DC6-:N(+FZ@T?2S?W%N+_`%2:ULKRYBL+4RW<EO:7,R1&."5E
MWPR,`P8$'!!!X(/0\=0<Y],5_+#_`,',\?QYU[P;^S=HO@7X=^/=5^$GA76_
M%_C[QSX\\,Z/J>J:'HOC6.WTS0?!5MK%[I$<[^'KG3]+O/%5S:WVJ+:VMZVL
MQQ:?=/<V=W&O\VGPN_X*:?M^?!"R@T7P#^U+\6-(TRQ016^BZ[J\'B_3K15Q
MA8M+\;66OVL!X`.V!21\I^7BM>%/!C'\8<-83/<KSW+:>*Q%7$1JY;BN>]"%
M&O.C"4ZU!UI0G4C#VBISPZ]V46Y78Z>%=2G&:FDW>ZM=+_@];=K'^CW^TCKO
MPQ\.?`'XPZQ\99-*C^%]G\./&#>-TUAX197/A^30[V/4+$K.RK-=7\+&SL+:
M/-S<WTUO!:JUR\2G_*=M+6YO[JVL;&WFN[R]N(+.TM+>-I;BYNKF588+>&)`
M7EFGE=(XXU4L\CA1DL*^N?CK^W3^V5^UA:0^&_C7\>/B-\2]':Y2XA\)-<0:
M?X>ENP?W<O\`PBOA>PTK1IYU;'E,VG.ZD*$QA<?M/_P1H_X(V_%KQU\4OA]^
MU3^TMX-O_`'PB\#ZE:>,/`W@CQ;I\VG>*_B/X@TZ2*[\.:E=>'[Z&.[TCP=9
MWBQZK'=ZG%;7.NM;6?\`9MO)IMR-0/[-PKD>&\%.&.(<?Q+G>#KXW,81E0R_
M"SER5*M"E5C0H8>%50J5\17G4M.I[&$*<%[S<(RD=5.,<+3DYR7,]4DWKI:U
MNNOR5C^VB[L;._M9K*_M;>^L[B-HKBUNX8KFWGB<$/%-!*KQ2QL"0R.K*P."
M#7SOXA_8Z_91\570O?$/[.'P4U6\\U)C<W'PU\)>:TR!@LCO'I2,[`,02Y;/
M&[)`-?25%?QQ0Q>*PK;PV)Q&';W="M4I7]>24;_,\*MA,+B/]XPU"O\`]?:-
M.I;KISQ?4\V\#?!SX2_#(./AU\,O`/@5I%:.63PEX1T'P]/-&S[RDT^E6-K-
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MTG5C:U5TX.HK;6FUS*W2S"BBBLC4*Y'Q=\/_``'\0+2&P\>>"O"7C6QMI?/M
M[+Q;X<T?Q':03@$":&VUBSO(8I<$CS$17QQNQ7745<)SIR4Z<YTYK:4).,EZ
M2BTU]Y$Z=.I%PJ0A4B]XSBIQ?JI)H\/_`.&9/V;?^C??@C_X:GP)_P#*&C_A
MF3]FW_HWWX(_^&I\"?\`RAKW"BM_KV-_Z#,5_P"%%7_Y,P^H8'_H#PO_`(3T
M?_D/)?<<;X.^'7P^^'=O>VGP_P#`O@[P-::E-'<ZA:^#_#.B^&K>_N(4,44]
MY#HME91W4T49,<<LZNZ(2BL%.*[*BBN><YU).=24ISEK*4Y.4GTUDVV]--6;
MPIPIQ4*<(4X+10A%1BK]HQ22^2/&I_V<_P!GRZOIM3N?@5\'+C4KBZ>^GU"?
MX9>"IKZ>^EE-Q+>37<FB-<274D[-,]P\C3/*3(SER37L4<:1(D42+''&BQQQ
MHH5$1`%1$50%554!54`````8I]%74K5JJBJM6K44-(*I4E-13MI%2;Y=EM;9
M=B:="C2<G2HTJ3F[S=.G"#D^\G%+F>O6YFZQHVD>(=+O]#U_2M.US1=5M9K'
M5-(U>QMM2TO4K*X0QW%G?V%Y%-:7EK/&2DUO<1212H2KHRDBO/?#?P+^"7@[
M6;/Q'X0^#WPM\*^(=/\`M`L-=\.?#_PGH>LV0N[::RNA::GIFDVM[;"YL[BX
MM+@0SIYUM/-!)NBE=&]4HHC6K0A*G"K5A3G?GA&I*,)W5GS132E=:.Z>F@3H
M4:DXU)T:4YP^"<Z<)3CK?W9--QUUT:U"N/\`&'P]\`_$.UM+'Q_X'\(>.+*P
MG>ZL;/Q?X:T;Q+:V5S(GEO<6EOK-E>Q6\[Q_NVEA1)&3Y"Q7BNPHJ(3G3DIP
ME*$XN\90DXR3[J2::?HRYPA4BX5(QG"6CC.*E%^L6FG\T<-X.^&'PU^'9OC\
M/_AYX'\#'4Q"-2/@_P`)Z#X:.H"W+FW%Z=%L+(W8@,DAA$_F",NY3&XY[FBB
MG.<ZDG.I.=2;M><Y.4G965Y2;;LDDKO84*=.E%0IPA3@MH0BH15]7:,4DM>R
M/S(_X*`_LKW?Q)TA?BYX!TT7/C/PS8,GB32[2-1=^)/#]HID6XA52INM5T6)
M9&@A&ZYO++-G`)9H;2!OS+_9=_:?\3?LW^+)9XX9M:\$ZU-''XJ\,-.T+94I
M%_:^F%@T<&KV4:@8D3RKVW0V<[Q9@N;7^FH@,"K`$$$$$9!!Z@BOS!_:J_X)
M^Z9\0KN]\>_!W[!X=\77!DN-9\,S?Z-H7B*<@L;JS=04T?4Y#GSMJ&QO7;S9
M5MYS+/-_+WBMX5Y_A\^I^)/AM.=#B'#35?,LNH-*6-E!)2Q&'IOW*U2K33AB
M\+)6Q,;RC>HVI_FW%/"^/ACX\2<-MT\QI-3Q.&A9/$-))U*<7[LYRC=5J3TJ
MJ[5YMW^\OA;\7?`'QD\,VWBGP'X@LM8L)T475JDL:ZEI-SM!DL=6L"WVFPNX
MR<B*X1?-B*7%NTMO+%*_S!^TQ_P35_8I_:WFNM2^-/P-\,:KXINHBA\;^'7O
M?!OC4/G<D\OB/PO<Z9?:A(CX;9JK:A;S!1%<P3P9B/X<.OQH_9R\9M&X\6?#
M+Q;:D-TN=/6_MU<A98VYL-9TUW#*DL;7=E(P<*[,&`^U/AY_P4\^+'A^&&T\
M?>%/#GCZ&)43^T;2:;PMK3C@-)<R6T.HZ5<LJY*QPZ58>8>))LMO7MX)^E)@
M\LK4J'%5+.>#.(L):CB<;@H8N%!SC92DX4+8[#\S5Y4G2K0W]_ET*RKQ*P<;
M8?/*&(RK&T[1JSC2J3HN2LFW"*=:D[Z\KA-+^8\SU'_@V5_8*O;ZXNK;XF?M
M5Z3;S2[H],L/'WPMELK5,+^ZMY-5^"NIZB\>1DFZO[B7EOWF,`?77P"_X(??
M\$[/@!>V&M6'P>N?B;XFTZ2*6V\0_&+Q!=>-Y5FA*-',OA\0Z7X*BG21?,2:
M#PO%*K$@2>7M1;\'_!5;P6T*&Z^%7BB.?&9$@U;2YHE8'@)+(('88P26B3GC
M!'-<=XK_`."J]S);30^"?A/'%=O&WV>_\3^(&>"!^=CRZ7I=FKW2@X)1-7M,
M\@2#@C]?S'Z7&0UL#4ABO%#-L50G"TL/1EG#J5HM?!*-.A&3YEHU4DHW;4VD
MSZ*IXA<.1@Y/.$[*_+3HXAU'L[65%--[/F<=;W:/U^BATCPYI45O!%IVBZ+I
M5LD<$,,=MINF:;8VL>U8XH8Q#:VEI;0H`J(L<,48``55Q7Y._M7_`/!0>TL8
M;_X?_`/4TNM2+M:ZO\0K<"2SLE1L3VWA=W)CN[I\&)M8,<EK"C.^G^;*8;R'
M\\?BG^U!\=/CM,=+\4>)[R73;^=(+?PAX7M9-.T>9YI`(;1-/M&FO-29Y)!'
M$NH7.H7$C%$WN0@7Z'^`?_!._P")'Q($&N_$N2]^&WA::%Y8+.:V0^++YGB/
MV?&G7(V:3"9"DLCZE&;EHU:);)&E$T?\X\1^,?&/B55J\-^%&29G2I5W*&+S
MZM'V.)5-VYO9UN;V&71G?6M5K^WDG:"A)Z?%9AQAG'$DIY;PG@<5",]*N/FE
M"HH]>2?-[+#)_P`\ZG.[^[RMH^^/V3_VX/"GQAT_3/!GCV]L_#/Q/@@CM?\`
M2I(K/2?%L\0V"XTB9W6./4+D8DFTAMDAE:3[")HE(7[RU;2-'\1:7>:/KNEZ
M=K>CZG;O::CI6J6=MJ6FW]K,N);:]L;N.:UNK>1>'AGBDC8?>4BOYK/CK^R#
M\7_@/=76H7^DW'B/P=;2[[;QKX?@FGLH(=^(9-7@C\RYT28?)N:ZS:!RJQ7D
MKD"MGX4_MT?M`?"R*WT^/Q';>,]"@\N-=(\:03ZFT4*_+Y=KJL-S::O`0@Q$
M'O)X`WS/;2#@]/"WCWG'!\Z7#?BKDN:8/,,"XT:>=4:#]K5A3:C"KB*3<%7<
M4E)XK"3G[32:IN3N],KX[Q>4-99Q7@L50Q%"U-8V%*[G&*45.K"Z5335UJ+E
MSI_`WO\`H!\7?^"+G_!-[XS7]UK'B#]G+1?#6M74KS3:G\.->\3?#UGGE.Z2
M:33O"VK:?HEP[DY+76EW&#DJ%/->*^$O^#?/_@FCX7U1-2O_`(:^/?&8B>-X
M=.\6_%+Q7)IBR1ECE[;0+GP^UTCDCS(;R6YMV"*IAVEP_=Z%_P`%6=--NB^)
M?A#?VURJ@.^B>)8+Z"5\'++'?:=I[PJQY"&2<H#MWN1DZUW_`,%5?"2PDZ?\
M)_$<]SNRD=WKFFVD!/;?-##>R+SC.(&XR1Z5_0.%^EAPY1P2I8?Q2SBAA53:
M5!U\]A.G#E2]G&FZ7M865DHPLD_AWN_L(^('#3IJ2SF*C;X72Q*FMFUR.CS7
M6FW79NY]Z_!3]FCX!?LY:0^A_`_X1^!/AEITD:QW'_"*>'['3KZ]1"&`U'5$
MB.I:@`PWXO+N<>83)C>S,?4)O%?ABWUZW\,W'B'1H?$=Y:27MIH4NI6D>L7%
MG"ZI-<P:<THNY8$=@K3+$45LKNR#C\*?B)_P4;^-OC=;C3_"EIH?PXTJX7:6
MTI9=8\1!7#!E.MZ@([6,!2FR2QT6QN4<,?M#*P5?FJU?X@Z@_P#PLB^'B^Y$
MFJ!&\<S1ZN\7]K*%9(E\1;/*2^1%.R%+M9412$157`_)<^^DUE6+QS_U>R[-
MN*)^U57,,QQ7MZ,?JR:=2I!U(U<5*?+>U3$TZ4(2:3YCP,9XDX%U53RO"8G,
M>5QE6K3C.C35+1S<$XRJ-V=E*I&$4UK=']1@SD^G&#ZUYEXF^"OP:\;:DVL^
M,?A-\,_%NL.BQOJOB;P+X7U[4FC4`(C7VJ:7=W3(H`"J92H```XK\GOA7^V=
M\8O#$5OIVLWECXUTN':BQZ]$Z:FD:X^6+5[-HIV8YQOOXM0V@`(JXY^R?#_[
M:NE:I$OV[P+?V<[A05L]6MKR$$EA_K)K:Q;I@Y\KOCM7W_#OC1PAFU*%6GC\
M9E.)G%*>'Q-&O"I%NS<?;X95*4H]O?BWNX+8^@P'&638V":KU,+4:UIUJ<TU
MM?WZ:G!I-Z>\FUK9;+W?_AF7]F__`*-^^"7_`(:KP+_\H:/^&9?V;_\`HW[X
M)?\`AJO`O_RAKDK']I+3]31!9>&;P.RYQ<WL$:@=!\T4<Y/.<_(,8Z'/':Z1
MXWU?7Y$WK!9PL?\`4VX8M@G&&FE)+''`,:Q@Y.4X&/O,/QIA,9*,<'FN*Q3G
MHO9U<2E?3>4W%==;7MV/;I9MA:[2HUY5.9I+EY^O^*WX7/1?#/A'PIX*T>'P
M_P"#/#6@>$M!MY9YK?1?#&CZ=H.D037,K37,L.FZ7;6ME%)<3.\L[QPJTTK-
M)(6<DUT506QS!$3R=HS_`/7]_4GD]:GKU>=U/?DW*4_><I-N3<M6VWJV[ZM[
ML[;WU[ZZ^9Y=XD^!_P`%O&6J2ZYXO^$/PP\5:U.J)/K'B3P%X5US5)DCR(TE
MU#4]*NKN14!(17F(7)V@9K!_X9E_9O\`^C?O@E_X:KP+_P#*&O;Z*Z8XS&12
MC'%8F,8I)1C7JI)+1))2LDNB17/+^:7WO_,\0_X9E_9O_P"C?O@E_P"&J\"_
M_*&O3?"_A#PGX'TF/0/!?ACP]X1T*&::XAT7PQHVG:!I,4]R_F7$T>G:5;6E
MG'-<2'?-(D(>5_FD9FYKHJ*FIB<16CRU<17JQO?EJ5:DXW5[.TI-75WKOJQ.
M4GNV_5MD<L44\;Q31I+%(K))'(H=)$<%71T8%61E)5E8%6!P017S3XS_`&,/
MV2_B%<RWOC/]G#X+^(;RX#"XN[_X=^%S<S[RI9I9X=-BEE=BBDO(S,<<MUKZ
M:HIX?%XO"2<L+B<1AI/>6'K5*+?JZ<HM_,%)K9M>C/G[X?\`[*'[,WPJNH;[
MX<_`3X2^#;^V\O[-J&A>`_#=EJ%N8@BQFWOTT_[9`R"-,-%.C94$DFO?QTQC
M`[#V^E.HJ:^)Q&*GSXFO6Q$[6YZ]6=65NW-.4G^(-M[MOU"BBBL1!1110`44
M44`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%,?I^/]#1
M10!RWB_P5X1\;Z7)I7B_PUHOB73VW'[+K.GVU_$CE2/,A^T1NT$N.!+"T<@!
M(##)K\C_`-J+]G+X+>$K:]U+PUX&L]%NU:4*;'5-?BMU"PS.`ME_:ILEPR@_
M+;C.,'(XHHK\:\6LGRG%Y:Z^*RO+L374=*V(P6&K55K%:5*E*4U\F?)<5X/"
M5L%*I6PN&JU%RVJ5*%*<U[R6DI1<EIIOL?D?=HL5S<QH"J1SW"(-S'"QRLJ#
M)))PH`R22>I)-?8_[,?PH\`?$'4+2/Q?H`UA&7<RMJ>LV08K-=`;AINHV>1B
M)`5/RG;R#ELE%?RWP]D^45<XPU.KE>75:;J6<*F!PTX/WEO&5)Q?S1^6Y7@\
M'/'8>,\+AIQ=2*<94*4HOWENG%IG[H_"CX(?"3X=V5K>>#/A_P"&]"OFAC)U
M&WL%GU/+(%?&I7K7-^N]21(%N`'!^?->YC@X'0`8'YT45_=W#V"P>!RK"4L%
MA,-@Z?L8/V>%H4L/#9?8I0A'\#]TP5&C0PU&%"E2HP]G!\M*G"G'9?9@DOP(
MO+CEC:.5%D1LJR.`RL",$$'@@C@@\&OC3XW?LR?`77[*YU;4/ACX<CU*9B\M
MYI27N@3R.?F+.VA7>F[F9OF8D98DELDFBBO)XVRW+LPR>NL?@,%C5&+LL7A:
M&)2UCLJU.:7R.;-\-A\1A*BQ%"C72CHJU*%5+WH[*<9)'X-_&+POH?A7Q#+8
MZ#8FPM5NKV(1?:KRZPD2P&-=][<7$GREVYW[CG!)`&.3\!Z58:QXDM+#4H/M
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M4KTXWYE"*YK];WN?)7Q:^`7P>CMKS5+;P'I%A>F.6<RZ6]_I*F4`88P:;>6M
MN1_L^5L_V:^#+G3K/3-<:TL8?(MTVE8_,EEQB:5?OS/(YX4=6/(SU)-%%?G?
M%>5971S;FHY;@*4I3;E*E@\/3E)\V\G"FFWYL^;SK"X:GC$Z>&H0<FFW"C3B
MV]-6U%7?J?1_PNLK:^O88KJ/S8\)\N^2/JTF>8G1NP[U]^>%]`T>QMHGMK"*
M-MBG<S22MRN3\TSR'J/6BBOT'@[#X>-)RC0HQDHJTE2@FO1J-T?0Y+3IJ":I
KP325FHQ36G1I'9C[S?\``?Y4ZBBOT0^@"BBB@`HHHH`****`"BBB@#__V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
